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ABSTRACT
BASHAR WADIH BADRAN. Transcutaneous Auricular Vagus Nerve Stimulation
(taVNS): Development, Safety, Parametric Optimization, and Neurophysiological
Effects. (Under the direction of Mark S. George)
Cervically implanted vagus nerve stimulation (VNS) is a FDA-approved treatment for
epilepsy and major depressive disorder (MDD). Additionally, VNS is a reemerging area
of interest, showing promise in numerous animal studies with significant translatable
applications. The cost, surgical risk, and human translation difficulty makes noninvasive
VNS a highly-desired alternative.

We have developed a transcutaneous auricular vagus nerve stimulation (taVNS) system
that electrically stimulates the auricular branch of the vagus nerve (ABVN). We aimed to
answer the following questions in this body of work: 1) whether taVNS is safe and
feasible 2) if taVNS stimulates the vagus system similarly to implanted VNS 3) if the
neurobiological effect of taVNS is similar to implanted VNS.

We measured physiological recordings in healthy adults during taVNS to determine
whether taVNS has vagus-mediated effects. In our first trial (n=15), we explored the
physiological effects of 9 various stimulation parameter combinations (various pulse
widths and frequencies) as a broad search of the physiological effect. A second, followxiii

up trial was conducted (n=20) to determine the best candidate parameter that optimally
activates the parasympathetic nervous system. Lastly, we developed and conducted a
novel concurrent taVNS/fMRI trial (n=17) to determine the neurobiological effect of
taVNS and its afferent targets. All three trials consisted of 2 visits each, in a randomized,
controlled, crossover design in which taVNS was delivered to either the left tragus
(active) or earlobe (control).

The first physiological trial revealed relevant, immediate heart rate decreases during
taVNS followed by a sympathetic rebound upon termination of stimulation. Of the nine
parameters tested, two had the largest effect on heart rate (500µs, 10Hz; 500µs, 25Hz).
These two parameters were tested in the follow-up trial, which demonstrated that both
parameters decrease heart rate, with 500µs 10Hz having the largest physiologic effect.
Lastly, findings from the taVNS/fMRI trial demonstrate the neurobiological effect of
taVNS mimics that of cervically implanted VNS and targets several cortical and
subcortical vagus afferent pathway targets.

taVNS in our paradigms was feasible, safe, and demonstrated neurobiological effects that
are similar to implantable VNS. Future trials should conduct parametric optimization
using the taVNS/fMRI protocol as it reliably targets vagus nerve afferents as well as
further explore optimizing taVNS as a possible therapeutic and research tool.

xiv

CHAPTER 1
OVERVIEW OF VAGUS NERVE STIMULATION (VNS)

Human Anatomy of the Vagus Nerve
Cranial Nerve X
Cranial nerves (CN) serve as a pathway for which information is exchanged between the
central nervous system (CNS) and the periphery. It would not be possible to integrate
outside sensory information with the CNS without CNs. There are 12 cranial nerves (1),
all of which play an important role in human sensation and perception. Important senses
relied on daily, such as smell (CN I), vision (CN II), hearing (CN VIII), and taste (CN
IX) are all relayed to the brain from the periphery via cranial nerves. 10 of the 12 CN’s
first point of entry into the CNS is through the brainstem and have widespread afferent
cortical and subcortical targets and effects.

CN X, otherwise known as the vagus nerve, is a mixed sensory and motor nerve that
originates from the medulla in a region known as the nucleus tractus solitarius (NTS).
Latin for “wandering nerve,” the vagus nerve’s efferent projections travel throughout the
thorax and abdomen, targeting nearly every major organ in the body. The vagus nerve’s
primary role serves to monitor and regulate the organs depicted in figure 1-1a (2)
1

Figure 1-1 Schema of the Vagus Nerve. a) Visualization of the vagus nerve path
through the human torso. The vagus nerve exits the brain and wanders vertically down
through the entire human torso targeting nearly every major organ in the body. Listed are
some of the major organs and their functions modulated by the vagus nerve. b) A cross
section of the vagus nerve. This cross-sectional diagram demonstrates how the vagus
nerve is composed of multiple bundles of nerves. The vagus nerve houses over 100,000
individual nerves, each compartmentalized into bundles and surrounded by gristle. These
numerous bundles form one large nerve known as the vagus.
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and convey information to the CNS (afferent projections) as well as from the CNS to the
organs (efferent projections). It’s efferent effect is primarily parasympathetic (3), as the
vagus releases acetylcholine (ACh) onto its targets, which binds to muscarinic Ach
receptors inducing their behavioral effects.

The vagus nerve is not one large nerve, but rather a large track of nerve bundles
surrounded by gristle (Figure 1-1b) housing over 100,000 individual nerves. These
nerves are about 80% afferent projecting nerves and 20% efferent nerves (4), although it
is nearly impossible to determine exactly which nerves serve what purpose given its
complexity. It is also extremely difficult to isolate behavioral or physiological effects
from an individual nerve within the bundle, as intricate in-vivo microsurgery is required.

Peripheral Targets
Nearly every major organ in the human body has a connection to the vagus nerve, which
enables bidirectional communication of information regarding relevant bodily functions
performed by the organ. Summarized in (Figure 1-2) are functional domains that these
target organs can be classified into: cardiovascular (heart), ingestion (esophagus, tongue),
metabolism (stomach, intestine), inflammation (spleen), glucose regulation and toxin
filtration (pancreas, liver, kidney). These domains are integral to daily life activities and
are constantly monitored by the CNS via the vagus nerve.

3

Figure 1-2 Behavioral domains that the vagus nerve regulates. The vagus nerve has
bi-directional communication with the periphery. It receives input from these organs as
well as sends centrally driven information to them to regulate their action. This vast twoway communication tract can be utilized to treat peripheral diseases of target organs and
central neuropsychiatric diseases.
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Afferent (periphery to central) vagal communication can be easily exemplified by the
feeding satiety signal. Cholecystokinin (CKK) and leptin are produced in the gut when an
individual eats and stomach fills with food. CCK and leptin generate a satiety “signal”
transmitted from the stomach to the CNS via the vagus nerve. This signal alerts the brain
and elicits a termination of feeding behavior (5, 6).

An example of efferent vagal communication is best demonstrated by the
parasympathetic relaxation of heart rate (7, 8). This parasympathetic response is initiated
in the periventricular nucleus (PVN) of the hypothalamus, sending efferent projections
down through the NTS and to the heart and lungs, releasing ACh and slowing heart rate
(9). This bidirectional communication and direct regulation of function of vital bodily
organs makes for an extremely large and intricate nerve system.

Afferent Brain Targets
The first entry point of the vagus nerve into the CNS (Figure 1-3) is the NTS (10, 11).
From the NTS there are direct projections to the locus coeruleus (LC) and parabrachial
nucleus (PB) (12). These two brain regions are responsible for many of the behavioral
effects of vagus nerve stimulation (VNS), which will be discussed in the later part of this
chapter. Krahl et al demonstrated lesions of the LC cause the anti-epileptic effect of VNS
to disappear (13) which confirm the LC main role as a vagus central hub.

5

Figure 1-3 Afferent pathway of the vagus nerve. The first point of entry of the vagus
nerve is in the nucleus tractus solitarius (NTS). From there the signal is immediately
projected up to the locus coeruleus (LC), the primary producer of norepinephrine for the
brain. From there the signal propagates in three directions 1) directly to the cerebellum
(CB) 2) up to the thalamus (THAL), and 3) frontally to the hypothalamus (Hyp),
amygdala (Amg), and nucleus basalis (NBM). Passing these deeper brain structures, the
afferent path leads to important mood and cognitive processing networks like the orbital
frontal cortex (OFC), cingulate cortex (Cing), and prefrontal cortex (PFC). Effects are not
limited to the named structures, as there are unlisted widespread, diffuse cortical effects.
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The LC is the primary producer of norepinephrine (NE) in the CNS, a key
neurotransmitter and alert signal of the brain. From the LC there are ascending
projections branching directly to the thalamus (Thal), hypothalamus (Hyp), cerebellum
(CB), orbitofrontal cortex (OFC), prefrontal cortex (PFC), cingulate gyrus (Cing),
amygdala (Amg) nucleus basalis of meynert (NBM) and the rest of the cerebrum (14).

Although NE is the primary afferent neurotransmitter involved in the afferent vagal
pathway, the LC also influences serotonin release through direct projections to the dorsal
raphe nucleus (DRN) (15) which is the brain’s primary producer of serotonin and
independently has a wide range of ascending brain targets, many of which overlap the
ascending LC pathway.

Early Vagus Nerve Stimulation
Initial Animal Trials Exploring VNS
In the early 20th century, Otto Loewi conducted a famous experiment (16) that is credited
with discovering neurotransmitter communication in nerves. Loewi stimulated the intact
nerve of a frog heart maintained in a solitary perfusion chamber. He observed the slowing
of heart rate and collected the chamber fluid, transferring the fluid to a second chamber,
which contained a denervated frog heart. When the second, untethered heart was bathed
in the new fluid, it beat rate also slowed. This study concluded that the fluid must contain
a chemical released upon electrical stimulation of the nerve which Loewi called
“vagusstoff.” Eventually, this chemical was validated and now known as acetylcholine
7

(ACh). This discovery earned Loewi the Nobel Prize in Physiology or Medicine in 1936,
shared with Sir Henry Hallett Dale for “their discoveries relating to chemical
transmission of nerve impulses.”

Following Loewi’s experiment which demonstrated th peripheral effects of direct
electrical VNS, there were several important animal studies (Table 1-1) exploring the
central effects of VNS leading up to the inception of VNS as a human therapeutic tool to
eventually be used for intractable epilepsy and major depressive disorder (MDD). These
trials span a series of half a decade and are not assumed to be the only VNS trials
conducted during this time, but rather pivotal positive trials that served as integral
findings in the development of VNS as a modality. They all involve direct, in-vivo
electrical stimulation of the vagus nerve, as Loewi did to demonstrate neuronal and
behavioral changes.

Bailey and Bremer conducted the first of these studies in 1938 (17). This study
demonstrated that VNS in cats increased synchronized electrical potentials of the orbital
frontal cortex as measured by electrogram. VNS was then conducted in monkeys under
anesthesia by MacLean and Pribram in 1949 and reported in MacLean’s book in 1990
(18). Their study suggested changes in the lateral frontal cortex associated with
stimulation. Dell and Olson conducted their own VNS study in awake cats in 1951 (19)
which demonstrated relevant slow-wave changes in the amygdala and thalamus. Radna
and MacLean followed up with a second VNS trial with monkeys in which they
8

Table 1-1. Early VNS studies leading to human trials
Year Author

Model

Brain region

1938 Bailey & Bremer
MacLean &
1949 Pribram

Cats

OFC

1951 Dell & Olsen
1981 Radna & MacLean
1981 Radna & MacLean

Monkeys
Awake
cats
Monkeys
Monkeys

LFC
Amg, Thal,
ARS
Limbic
Striopallidum

1987 Zabara et al.

Dogs

Cortical

1992 Zabara et al.

Dogs

Cortical

Findings
↑ synchronized electrical
signals on EEG
Inconsistent, slow waves
on EEG
Slow wave response on
EEG
↑ single unit activity
↑ single unit activity
Medication-induced
seizure termination.
Protection 4x stimulation
period. Parameters
established.

OFC-Orbital Frontal Cortex; LFC-Lateral Frontal Cortex; Amg-Amygdala, ThalThalamus, ARS-Anterior Rhinal Sulcus
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demonstrated single unit activity effects as a result of stimulation in the thalamus,
cingulate, and limbic structures (20, 21).

The invention of therapeutic VNS is credited to Dr. Jacob Zabara, who was the first
individual to consider VNS as a treatment for neurological disorder. In the late 1980’s,
Zabara conducted a VNS trial in dogs that had pharmacologically induced seizure
disorder (strychnine) (22, 23). VNS in these dogs elicited cortical changes as measured
by EEG and halted motor seizures and tremors. He then conducted a follow-up trial,
again in canines, optimizing VNS as a seizure suppressor and also demonstrated that
VNS had a behaviorally positive long-term effect that persisted beyond the stimulation
period (24). These studies are cited as the pivotal animal trials that justified VNS as an
implantable therapeutic device for humans.

VNS for Epilepsy in Humans
Although Zabara is credited with the innovated application of therapeutic VNS in 1985, it
is forgotten that a century prior, an American neurologist by the name of James Leonard
Corning suggested that seizures could be attenuated using transcutaneous vagal nerve
stimulation through the neck. In 1883 (25, 26) Corning built a device (Figure 1-4, US
National Library of Medicine Public Domain) which he hypothesized would stimulate
the vagus nerve, decrease cerebral blood flow, and reduce epileptic seizure frequency and
duration. He also suggested it be used as a prophylactic therapy. Unfortunately for

10

Figure 1-4. The Corning fork. Developed in 1883 by James L. Corning, this device
served two purposes 1) bilateral carotid compression, which was believed to treat
epilepsy, and 2) direct electrical stimulation to the carotid sheath, stimulating the bilateral
pneumogastric nerves as a prophylactic epilepsy therapy. This figure is from the US
National Library of Medicine where the original manuscript may be found and falls under
public domain use (26).

11

Corning, his colleagues did not adopt his technology and it disappeared by the early
1900’s.

In 1987, Zabara co-founded Cyberonics, Inc. (now LivaNova), along with Reese Terry,
and began developing a human VNS device based on his promising animal trials. The
first human implanted with a VNS device was in 1988 at Wake Forest Gray Medical
School in North Carolina by Dr. J. Kiffen Penry and neurosurgeon William Bell (27).
Eventually, four patients were implanted in this inconclusive safety and feasibility trial.
Side effects were described (hoarseness, stimulation sensation, hiccups). Several more
clinical trials (28, 29) were conducted in the early 1990’s leading up to European
approval of the Cyberonics VNS device to treat epilepsy in 1994 (30, 31), and subsequent
United States FDA approval in 1997. Degorgio et al (32) demonstrated nearly 20% of
individuals had a >75% reduction in seizure frequency at 12-months post implantation,
and a median reduction on seizure frequency of nearly 50%. Sackeim et al (33)
demonstrated the acute response rate in refractory epilepsy as being approximately 30%.
As of 2017, according to Cyberonics, over 100,000 patients worldwide have been
implanted with a VNS device as a treatment for intractable epilepsy.

Modern Vagus Nerve Stimulation
Implantation and Programming
A VNS system can be implanted by any surgeon trained in the head and neck. It is an
outpatient surgical procedure with few serious complications (32, 33). The implantation
12

site is the left branch of the mid-cervical vagus nerve, which is accessed through the
neck. A helical bipolar electrode (three-helix cuff) is wrapped around the nerve (Figure
1-5). Wires are run from the electrode cuff to a subcutaneously implanted pulse generator
in the left chest. This pulse generator, or “can” contains a lithium battery and constant
current pulse generator with a lifespan of approximately 5 years although second
generation devices are being developed to have lifespans of over 10 years.

Following implantation, there is a two-week period in which the patient can recover from
the minor procedure. The patient then returns after this two-week period to have their
pulse generator programmed by their providing physician in an outpatient setting.
Programming of the device is completely wireless, using a proprietary wand that
connects to the device using radio frequency (RF). Through a portable computer, the
wand can program specific parameters (current (mA), duty cycle (on/off time) and
frequency (Hz)). The pulse generator also contains a reed switch, which enables the
patient to turn off the device by swiping a strong static magnet over it. This enables the
patient to test if the device is still functioning, but more importantly allows for user
control of the device in the case of side effects.

13

Figure 1-5. Modern cervically implanted VNS. a) VNS systems have two key
components 1) an implantable pulse generator (IPG) which contains a battery and
microcontroller delivering current, and 2) bipolar helical electrodes that wrap around the
left cervical vagus nerve. b) This zoom view of the vagus nerve demonstrates how the
electrodes are wrapped around the vagus nerve bundle.
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Parameters
The question of optimal parameters arises with every form of neuromodulatory
techniques such as transcranial magnetic stimulation (TMS), electroconvulsive therapy
(ECT) and deep brain stimulation (DBS). The parameter space for these modalities is
extremely vast. As presented in Figure 1-6, pulse width (µs), current (mA), frequency
(Hz), duty cycle (on/off time), and dose titration (% threshold) are all parameters that can
be manipulated to optimize desired behavioral response. Although the parameter space is
large, many of our current therapies are based on the effects seen in preclinical animal
studies, which are then translated to human studies.

Initial trials of the anti-seizure effect in a canine model demonstrated in Zabara’s trials
determined an optimal stimulation frequency of 20-30Hz, at a constant 20V with a pulse
width of 200µs (24). Those findings guided initial multi-site clinical trials that eventually
could determine optimal stimulation parameters to reduce seizure frequency in epilepsy
patients.

One notable difference is the pulse width increased by a magnitude of more than 2 (from
200µs to 500µs) from animal trials to human trials. This is a result of neuronal chronaxie,
which is the minimum pulse width size required to fire a nerve fiber using an electric
current. Imach and Ranck discuss that a pulse width of 200-700µs is the optimal pulse
width to fire nerve fibers as it maximizes the peak firing percentage rate while
minimizing inefficient excess and side effects (34, 35). Short pulse width would
15

Figure 1-6 Direct electrical current waveform. Direct square wave electrical current
can be delivered at various parameters. This figure demonstrates key properties of the
waveform that can be changed to achieve desired biologic effects.
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require significantly higher voltages to consistently and reliably depolarize nerves,
whereas larger pulse widths, although they maximally depolarize nerves, demonstrate
higher side effects and are using electrical energy from the device inefficiently.

Agnew and McCreery explored the question of optimal stimulation frequency the initial
1987 anti-epileptic findings by (36, 37). They demonstrated that higher frequency ranges
(>50Hz) in fact cause damage to the vagus nerve. This damage is not seen in lower
operating frequencies. Low frequencies (1Hz) were explored in human clinical trials as a
control (32) (38)and showed minimal behavioral effects, effectively constraining the
frequency space in humans to between 1Hz and 50Hz.

The current accepted parameters for VNS are as follows: current– 0.25-0.75mA; pulse
width– 250-500µs; frequency– 20-30Hz; duty cycle – On 30s, Off 5min. These
parameters are set as ranges and increased to a maximally tolerable level dependent on
immediate side effects listed as hoarseness of voice, throat pain, coughing and headache
(32, 33).

VNS for Resistant Depression
During the late 1990’s, as the VNS for epilepsy pivotal FDA-trials were coming to an
end, a clerk at the Florida hotel all follow-up patients stayed at noticed their moods were
improving. Anecdotally, and lacking objective depression measures, this was relayed to
the study team and followed-up by a prospective study in 14 individual (39) showing a
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trend of mood-enhancing effects of VNS. In retrospect, given the wreath of depression
neuroimaging research accessible today, VNS for depression is accepted to potentially
have an anti-depressant effect with its afferent brain targets.

Several multi-site trials were conducted in the early 2000’s to determine whether VNS
was an effective antidepressant in patients with extremely resistant major depressive
disorder (MDD). The first trial (33, 40, 41) was a four-site, open-label trial in 59 patients.
Acutely, 8 weeks of VNS produced a 31% response rate in these patients with a 15%
remission rate. Over time, these individuals improved, with the two-year response and
remission rates increasing to 44% and 22% respectively. European open-label trial
findings were similar to their US counterparts (42). These findings posed Cyberonics to
conduct a pivotal FDA-approval seeking randomized control trial in 222 extremely
resistant MDD patient. The findings of this pivotal trial were disappointing, with a large
sham response rate (10%) and reduced overall effect by condition, demonstrating nonsignificant acute benefits compared to sham (43). These patients were followed for two
years after implantation and the response rate more than doubled at two year follow up
compared to the acute treatment phase. There seems to be a cumulative, long-lasting
effect of VNS that is not being accounted for and is still unknown mechanistically.

VNS was FDA approved for chronic or recurrent depression in 2005 based on the
findings by George et al. (44). This study demonstrated that when VNS therapy was
compared against treatment as usual in a multi-site comparison trial with a followed, non18

implanted matched cohort receiving treatment as usual (TAU), VNS produced
significant, long-term, durable benefits. It still lacks class 1 evidence as a treatment for
depression and as of 2017 plans are being developed by LivaNova (acquired Cyberonics
in 2016) to conduct a pivotal, randomized controlled FDA trial for class 1 evidence of
VNS as a therapy for chronic recurrent depression.

Key VNS Functional Neuroimaging Trials
Several neuroimaging trials have been conducted using positron emission tomography
(PET) and functional magnetic resonance imaging (fMRI). Initial VNS imaging trials
were conducted in 1992 by Garnett et al using positron emission tomography (PET)
scanning (45). PET detects pairs of gamma rays, which are emitted by a radiotracer that
is injected into the patient and used as a measure of metabolism. Oxygen 15 (H215O PET)
is an excellent tracer for neuronal activity, as the cells require oxygen for metabolism and
neuronal firing. In this early trial in patients implanted with a stimulator for epilepsy,
VNS-increased blood flow was discovered in the thalamus and cingulate. This study was
followed-up by Henry and colleagues (46) who demonstrated areas of increased blood
flow in the brainstem, thalamus, and hypothalamus and decreased blood flow in the
medial temporal cortex and hippocampus. These two studies, although not inclusive of all
PET studies, provided the groundwork for functional neuroimaging that followed using
fMRI.
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fMRI uses strong magnetic fields (>1.5T) to measure blood oxygen level dependent
(BOLD) signals in the brain (47) that serve as a surrogate marker of neuronal activity.
Oxygen binds to hemoglobin and is carried to neurons in the brain for metabolism. The
differences in magnetic properties of oxygenated vs. deoxygenated hemoglobin make this
imaging modality possible.

Faraday’s law of induction dictates that electricity is induced when there is a changing
magnetic field around a coil of wire which poses concern for conducting fMRI combined
with VNS as the electrodes may heat up causing harm to the patient and the pulse
generator may function improperly due to the magnetic field of the scanner. Using a
specific orientation of implantation for the pulse generator as well as a specific head coil
to decrease the magnetic field delivered to the VNS system, Bohning et al (48) developed
the first VNS/fMRI method at the Medical University of South Carolina (MUSC). This
landmark study was followed by an important VNS/fMRI study in depressed adults
showing the frequency and dose effects of VNS in a pathologic group (49) and
subsequently by Mu et al (50).

Nahas et al (51) followed by conducting several longitudinal VNS/fMRI scans on
patients to explore the brain effects of VNS as a function of time. His findings reveal that
BOLD signals increased as a function of how depressed the patient was and how strong
the stimulation parameters were. Serially over time, these overall BOLD activations
decreased. Since then, there have been several VNS/fMRI studies from groups all over
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the world (48-54) demonstrating relevant BOLD signal intensity increases in vagal
afferent brain regions which are summarized in Table 1-2.

Recent Strides in VNS
Promising Animal Trials
VNS is seeing a resurgence in the scientific community over the past 15 years. In the late
1980’s and early 1990’s, much of the literature was attempting to determine the basic
feasibility and method of VNS. After that was established, the mid-1990’s to early 2000s
were dominated primarily by human clinical trials, translating the early animal studies
into two FDA-approved treatments for intractable epilepsy and chronic resistant
depression. Since the mid-2000’s to today, the field of basic VNS research has boomed,
with hundreds of papers being published a year on this interesting form of
neuromodulation. VNS has been explored in dozens of different disease animal models,
but the most promising are in the following central and peripheral disorders: obesity,
inflammation/sepsis, tinnitus and stroke. This section will highlight some of the hallmark
studies that are of high impact in the field and will most likely (if not already) be
translated into human studies.

The first promising animal trial exploring the effects of VNS (implanted in the thorax
near the stomach rather than cervical for epilepsy and depression) dates to 2001 in which
4 weeks of VNS in 27 rabbits demonstrated decreased food intake and weight loss
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Table 1-2. VNS/fMRI studies

Year

Author

n

Subjects

2001

Bohning et
al.

9

TRD

2002

Lomarev et
al.

6

TRD

2004

Mu et al.

12

TRD

2007

Nahas et al.

9

TRMD

Sucholeiki
et al.

4

Parameters
20 Hz; 500 µs; 0.51.25 mA; 13 sec on,
103 sec off
5 Hz or 20 Hz; 500
µs; 0.25-1.25 mA; 13
sec on, 103 sec off
20 Hz; 0.25-1.25 mA
(max tolerated at 500
µs); 13.6 sec on, 41
sec off
20 Hz; 500 µs;
variable mA; 13.6 sec
on, 41 sec off

Control

Findings

n/a

Feasibility of fMRI to measure
VNS effects on TRD patients
20 Hz > 5 Hz BOLD response.
20 Hz > 5 Hz to tone (arbitrary
stimulus)
130 µs - insufficient global
activation
250 µs - sufficient activation &
deactivation
500 µs - insufficient global
deactivation

Yes,
0 mA

VNS acutely activates R insula,
deactivates vmPFC.

n/a
Yes,
5 Hz
Tone

Feasibility of fMRI to measure
VNS effects on epilepsy patients
VNS induced ↑ activity in: b/l
30 Hz; 250 µs; 0.5thalami, b/l insula >> L BG, L
Narayanan
2.0 mA; 30 sec on, 30
Postcentral g, R post. STG, L>R
2002 et al.
5 Epilepsy
sec off (48 x1)
none
imOcc g.
2 patients with thalamic
30 Hz; 250 µs; 1.25activation has greatest seizure
1.75 mA; 30 sec on,
response. All patients had frontal
2003 Liu et al.
5 Epilepsy
66 sec off
and occipital activation.
TRD-Treatment resistant depression; TRMD-Treatment resistant mood disorders; vmPFC- ventromedial
Prefrontal Cortex; b/l- bilateral, R-right, L-left; BG-basal ganglia; STG- superior temporal gyrus; imOccinferomedial occipital gyrus
2002

Epilepsy

varied

*Refer to Dietrich et al. for review of areas of anatomic activation
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n/a

(55). There have been several follow-up trials since, demonstrating VNS decreases food
intake and weight gain (56-58). The most notable of these trials was the 2010 trial in
which obese Gottingen minipigs (58) were implanted with VNS devices and not only
lost weight but opted for a healthier diet. These findings translated to human clinical
trials in the 2012 EMPOWER randomized control trial (59) testing blockade of the vagus
nerve for weight loss. Unfortunately, the EMPOWER trial did not find significant
behavioral effects compared to sham. This trial was followed by a 2014 large scale,
multi-site RCT called ReCharge (60) which addressed limitations from the EMPOWER
trial and demonstrated significant, long-term weight loss benefits that eventually became
FDA-approved in 2015.

The human inflammatory system is a body’s natural response to pathogens and trauma.
These responses can be triggered by infectious and non-infections conditions (61) and
when left unchecked, the inflammatory cascade becomes a systemic response that can
become deadly. In 2000 a study published in Nature (62) described a landmark study in
which rats were given a lethal endotoxic event that was intended to develop into septic
shock. After administration of the endotoxin, electrical stimulation of the vagus nerve
decreased the release of pro-inflammatory cytokines (tumor necrosis factor (TNF),
interleukins 1B, 6, and 18). Ultimately this suppression of inflammatory cytokines
prevented the rats from entering septic shock from the endotoxin. Since then there have
been dozens of trials exploring the anti-inflammatory effect of VNS, most notably
attenuating heart failure progression in canines (63).
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Tinnitus is an auditory phantom perceptual disorder in which individuals hear a sound in
the absence of an external stimulus. The leading cause of tinnitus is acoustic trauma (64)
in which hair cells are damaged and no longer provide cochlear input of specific
environmental auditory frequencies, causing a spontaneous overexpression of that
frequency in the auditory cortex that presents as internally generated sound. To date there
are no effective treatments for tinnitus; often patients are sent home with this debilitating
condition and told to manage it on their own.

Michael Kilgard’s group at the University of Texas, Dallas have demonstrated that
pairing cervically implanted VNS in a tinnitus rat model paired with auditory stimulus is
able to reorganize the auditory cortex and reverse the pathological changes that induce
tinnitus(65-68). When VNS was delivered to the rats in a tinnitus model, there was no
decrease in tinnitus symptoms, neither were any symptom reductions seen with the tone
therapy alone. This suggests there is a synergistic effect of VNS combine with a paired
stimulus that is directing plastic changes to occur in the cortex. Kilgard calls this concept
“targeted plasticity”(66) in which various cortical targets can be selectively changed
dependent on the paired stimulus. This group is exploring VNS induced targeted
plasticity as a treatment for other neurological disorders in animal models involving
cortical reorganization, including stroke (69, 70) and have successfully moved into
human clinical trials for both these promising treatments (71-73).
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Lastly, VNS has been shown to rescue the brain if stimulation begins immediately after
trauma. In 2009 a study by Ay et al (74) demonstrated a rescuing effect of VNS in a rat
model of ischemic stroke. Rats that received vagal stimulation immediately after the focal
cerebral ischemia had not only significantly better neurological scores compared to the
control (non-VNS rats), but these rats also had infarcts that were nearly 50% smaller in
area than the control rats. This was replicated in 2011 by the same group (75) and is very
promising as a future potential immediate therapy for ischemic stroke. VNS seems to be
neuroprotective and keeps ischemia from spreading.

Noninvasive Vagus Nerve Stimulation (nVNS)
Although cervical VNS is relatively safe and effective in seizure prevention (30, 76), the
risks involved in surgical implantation as well as its high procedural cost (about $3050,000) makes it less appealing and accessible as a treatment modality. Additionally,
only about 30% of implanted patients have a clinical response, despite undergoing
surgery and spending large amounts of money. Having a non-invasive method as an
alternative or to determine ultimate responders would greatly improve VNS acceptance
as a treatment modality.

Noninvasive VNS (nVNS) can potentially be administered at two locations. The first and
most obvious method is via transcutaneous electrical stimulation of the cervical vagus
accessed through neck near the carotid artery (carotid sheath). This method, known as
transcutaneous cervical VNS (tcVNS) was first described 125 years ago by Corning (26).
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It can be delivered experimentally in a research setting by attaching transcutaneous
electrical nerve stimulation (TENS) electrodes to the neck and stimulating the underlying
tissue and nerve with either alternating or direct current high-frequency electrical
stimulation. A commercially available device, marketed as gammaCore, safely delivers
tcVNS (25Hz, constant current <60mA) to the cervical vagus nerve. This device has been
explored to treat various neurological disorders, including headache, migraine (77-80).
The optimal parameters and duty cycle is still unknown and needs to be developed
further, although as of early 2017 the gammaCore device gained US FDA-approval.

nVNS may also be administered through the auricular branch of the vagus nerve (ABVN)
that innervates the ear, more specifically the conchae and the external auditory canal (81).
This noninvasive method is called transcutaneous auricular vagus nerve stimulation
(taVNS) was first developed in 2000 (82). Since then, there have been several groups that
have conducted studies on this novel form of neuromodulation (83-88) which uses low
electrical current stimulation (<10mA) to stimulate the auricular vagus nerve. Many
laboratories conduct this novel method experimentally by building their own, miniature
electrodes that target this nerve and there is also a commercially available device
(European only, not for purchase in the US) called Nemos® claiming to treat epilepsy
using their proprietary device.

Whether nVNS enters the brain via the brainstem and targets vagal afferent brain regions
has been explored in a handful of studies combining nVNS with fMRI. There have only
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been five taVNS/fMRI trials in which stimulation was conducted concurrently with
imaging (89-93) and one tcVNS/fMRI trial (94). These studies are summarized in detail
in Chapter 4 of this dissertation. In general, these studies demonstrate similar findings to
the cervically implanted VNS/fMRI, with relevant BOLD signal activations and
deactivation in the afferent vagal brain regions (brainstem, thalamus, insula, amygdala).
Brainstem activation is inconsistently viewed in these functional imaging trials, as the
sample sizes are often small and breathing artifact often washes out this small region of
interest.

There are two major problems with nVNS: 1) the parameter space is unknown, and 2)
surrogate markers of vagal activation are difficult to determine. With cervically
implanted VNS, the vagus nerve is directly stimulated, whereas nVNS jumps through
several hoops to get to this point. Firstly, the electricity is delivered through the skin
targeting underlying nerves that are not visible. This requires more electricity to be
delivered in the case of tcVNS, potentially recruiting surrounding nerves
(glossopharyngeal nerve, laryngeal nerve) in the area and losing its focal effect, or in the
case of taVNS, recruitment of off target nerves in the area (auriculotemporal nerve, lesser
occipital nerve). taVNS still does not have a consensus target location to stimulate and
there is a debate that has arisen as to whether one targets the tragus or the conchae of the
ear. Aside from off-target questions, current stimulation parameters arise. Stimulation
current intensity (mA), frequency (Hz), and pulse width (µs) all vary throughout the
various early nVNS trials in the literature.
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Before the field begins large-scale use of nVNS, optimal stimulation targets and
parameters must be determined. It is common to rush to clinical trials with novel
methodology, but often these trials risk failure due to the lack of pre-clinical
optimization. This lack of optimization is the impetus for this dissertation body of work
which is consists of the systematic, parametric testing and optimization of taVNS which
is integral to guiding future trials. This dissertation describes three sequential studies
conducted at the Medical University of South Carolina. The first two experiments
determined feasibility, safety, and optimal taVNS parameters that modulate the
parasympathetic nervous system in healthy adults. We suspected that heart rate can be
used as a surrogate marker of vagal activation. The third experiment is a neuroimaging
trial which taVNS was administered in the fMRI scanner to explore the direct brain
effects. The combination of these three trials were planned to give this new field a
benchmark as to parametric-specific afferent and efferent effects of taVNS.
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CHAPTER 2
STUDY 1: A CONTROLLED TRIAL EXPLORING THE SAFETY,
FEASIBILITY and HEART RATE EFFECTS of taVNS

Study Summary
Background: Transcutaneous auricular vagus nerve stimulation (taVNS) is hypothesized
to stimulate the vagal system via the auricular branch of the vagus nerve (ABVN). The
optimal parameters of stimulation are still unknown and given the parasympathetic role
of the vagus nerve, it is important to establish a safety profile of this novel form of
stimulation, as well as the effect of various parameters on heart rate (HR).

Objective: The objective of this study is to investigate the safety profile and HR effects
of 1-minute sessions of nine various taVNS parameters (pulse width: 100µs, 200µs,
500µs; frequency: 1Hz, 10Hz, 25Hz).

Methods: We enrolled 15 healthy individuals in this 2-visit, controlled, crossover trial.
Each experiential visit was identical, in which participants received either active (tragus)
or control (earlobe) stimulation. 9 stimulation parameters were administered, each for 1
minute flanked by a baseline and recovery period. Participants were monitored for
adverse events while their HR was recorded the entirety of their visit. Statistical analysis
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was conducted on overall effect of condition (all 9 parameters combined; active vs
control) for the entire time course (120s) as well as a focused analysis on the independent
stimulation period (60s) and recovery period (60s). Multivariate analysis exploring the
individual parameter effects (active vs control) was also conducted.

Results: An overall effect of condition was revealed comparing active taVNS to control
for all parameters. No overall effect of condition was found on HR during the stimulation
period although active taVNS was found to significantly suppress the sympathetic HR
rebound in the post-stimulation period (p<0.001) compared to control. Upon multivariate
analysis, several parameters of higher pulse width and frequency (500µs 10Hz and 500µs
25Hz) significantly induced bradycardia during stimulation and attenuated the
sympathetic recovery spike (100µs, 10Hz and 500µs 10Hz).

Conclusion: taVNS is feasible and safe for 1-minute stimulation periods in healthy adults
with no adverse events observed. Two specific parameters (500µs 10Hz and 500µs 25Hz)
are revealed to be further studied as likely optimal parameters at modulating
parasympathetic response via vagal activation.

Introduction
Autonomic nervous system
The vagus nerve, as described in Chapter 1, is a large bundle of nerves that spans the
entire length of the body and targets every major bodily organ. The autonomic effect it
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has on these organs is primarily parasympathetic, with acetylcholine (ACh) being the key
neurotransmitter released on these organs and responsible for this effect (16).

The autonomic nervous system regulates vital organ behavior and is unconsciously
activated in response to certain sensory triggers, most notably affecting heart rate (HR),
respiration, and vasoconstriction/dilation (10). There are two independent and opposite
autonomic systems (95). The first, known as the sympathetic nervous system (SNS), is
generally accepted to be excitatory and accelerates HR, respiration, and vasoconstriction
of vessels. This is known as the “fight or flight” response which allows for heightened
arousal. The splanchnic nerve carries these excitatory signals to the viscera and release
norepinephrine onto its target organs. The second, independent system is the
parasympathetic nervous system (PNS), which slows HR and respiration. In general, it
elicits a slowing and relaxation of organs that are targeted. All parasympathetic nervous
system signals are sent via the vagus nerve, which releases Ach onto the organs to induce
the inhibitory effect. Both the SNS and PNS are tonically and reciprocally active to
maintain body homeostasis. Both the SNS and PNS activity arise from signals sent from
the hypothalamus, known as the central hub of the autonomic nervous system.

The Effect of Cervically Implanted VNS on HR
Otto Loewi demonstrated the slowing effects of the heart via the release of a ACh onto
the heart in the late 1900’s(16). Since then, as the autonomic nervous system was
studied, hundreds of studies have demonstrated the slowing of HR as a major response of
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activating the parasympathetic nervous system. This is easily demonstrated by the carotid
massage (96, 97), a procedure in which gently rubbing on the vagus nerve via the carotid
sinus stimulates the vagus and induces a parasympathetic slowing of the heart.

A major concern during the inception and development of vagus nerve stimulation (VNS)
is that direct electrical stimulation of the vagus nerve will elicit a powerful
parasympathetic response. During clinical trials, this was heavily monitored for and
tracked throughout implantation and treatment course (30). Anecdotally, there are
theories suggesting implanting a VNS electrode on the right cervical vagus could induce
more cardiac side effects than the left, although this was investigated in a VNS trial
exploring both left and right VNS for chronic heart failure which demonstrated equal
safety profiles (98).

There also have been several trials suggesting VNS has no effect on HR. Early VNS trials
by Holder (99) and Uthman (28) determined no change in HR in VNS implanted humans.
Ramsay (100) retrospectively determined there was no HR effect in acute monitoring of
epilepsy patients implanted with VNS. Setty A.B. and colleagues conducted a prospective
trial explored the effect of VNS on ten individuals implanted with VNS for epilepsy and
showed no change in cardiac rhythm during the 30s stimulation period (101). Contrary to
these three early studies, a recent study in 2001 by Frei and Osorio showed a decrease in
HR (bradycardia) immediately upon starting stimulation, followed by increased HR
(tachycardia)(102). Although this was the first description of immediate HR effects of
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VNS, their findings were highly variable between patients (no one consistent
physiological signature), although a consistent pattern within patients.

Rationale Behind Study 1
Stimulating the vagus nerve in humans elicits a decrease in HR. Since the therapeutic
VNS duty cycle is 30s and intensity relatively low, it is supposed that may explain the
lack of major HR adverse effects. To date, there have been no prospective studies
conducted directly exploring the effects electrical stimulation of the ABVN via taVNS
delivered to the ear on HR.

If stimulating the ABVN enters the vagus pathway, safety should be highly considered as
the parasympathetic effects of the vagus nerve may cause inadvertent adverse events. To
demonstrate the feasibility and safety profile of this novel form of stimulation that is
suspected to stimulate the vagus system, it is important to conduct a systematic,
parametric study exploring the HR effects of various taVNS parameters. Additionally,
given the large parameter space of taVNS, this trial was conducted to determine whether
some parameters modulate the vagal system and HR more effectively than others, using
HR modulation as a potential surrogate measure of optimal parameters. This is not
intended to be an exhaustive exploration of parameters but rather a reasonable
combination of high and low settings loosely based on prior cervically implanted trials
(24, 27). We hypothesize parameters of higher energy density (larger pulse width, faster
frequency) would be more effective at modulating HR in a similar manner as prior
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cervically implanted VNS trials (32) and these parameters could pose the highest safety
risk.

Methods
Overview
We conducted a 2-visit, controlled, crossover trial in healthy individuals exploring the
HR effects of taVNS. Individuals came to the Medical University of South Carolina
(MUSC) brain stimulation laboratory for two separate 1-hour experimental visits
(active/control visits, counterbalanced design). Each visit was identical except for
stimulation condition (Figure 2-1a). The trial was approved by MUSC Institutional
Review Board (IRB) and is registered on ClinicalTrials.org (NCT02835885).

Participants and Inclusion Criteria
15 healthy adults (7 female) were enrolled after meeting the following inclusion criteria:
Age 18-45, no personal or family history of seizure, mood, or cardiovascular disorders,
no facial or ear pain, no recent ear trauma, no metal implants including pacemakers, not
pregnant, no dependence on alcohol or recent illicit drug use, not on any pharmacological
agents known to increase seizure risk (Bupropion, neuroleptics, albuterol, theophylline,
antidepressants, thyroid medications, or stimulants).
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taVNS Stimulation System and Parameters
A custom developed stimulation system was developed at the MUSC Brain Stimulation
Laboratory and used in this trial. It consists of a commercially available, FDA-cleared
Digitimer DS7A constant current stimulator (Digitimer Ltd., USA) used with custombuilt electrodes (built by BWB and AWB) (Figure 2-2a). Electrodes had a stimulation
surface diameter of 1cm and Ten20 conductive paste (Weaver and Company, USA) was
used to deliver stimulation to ear targets. Participants lay supine with their neck and head
propped up in a comfortable position with a pillow. They were instructed to stay awake
and maintain a still, comfortable position. Stimulation targets were prepped with alcohol
swabs (70% isopropyl alcohol) to clean surface oils and decrease skin resistance.

Stimulation parameters varied by pulse width (100µs, 200µs, 500µs) and frequency (1Hz,
10Hz, 25Hz) creating 9 different combinations of stimulation parameters. These
parameters were chosen to cover a wide range (low to high) of pulse width and
frequencies. The current (mA) of electrical stimulation was delivered at 200% of each
participant’s individual perceptual threshold (PT). A PT was conducted for each of the
three pulse widths investigated in this trial (100µs, 200µs, 500µs) in which the lowest
electrical current perceived was recorded and repeated for each stimulation condition
(tragus and earlobe). This is due to the large impact pulse width has on PT as well as
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Figure 2-1 Overview of Study a) timeline demonstrating flow of participants through
trial. b) Experimental visit timeline. Each participant attended two identical visits
structured as presented in the figure.
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sensitivity variance between target sites. Each stimulation period lasted 1minute, flanked
by a 90s baseline and 180s recovery period. This is repeated 9 times, once for each
stimulation parameter in a randomized order between subjects (orders were kept identical
within both subject visits). See Figure 2-1b for an overview of experimental design.

Ear Stimulation Targets
This controlled study employed two different stimulation conditions (See Figure 2-2b).
The active condition was direct electrical stimulation delivered to the inner side of the left
tragus (anode on electrode in the outer ear canal, cathode on the surface of the tragus).
Currently there is a debate as to optimal active stimulation position. Some groups have
chosen to stimulate the conchae/pinna of the ear, whereas our group decided to stimulate
the inner part of the tragus. The tragus location was chosen based on the review of
several prior studies exploring the tragus nerve anatomy (81, 103), tragus-evoked
potentials (104-106), auricular acupuncture trials (107, 108), and an early taVNS/fMRI
trial (91). More generally, the hypothesis is derived from the idea that the tragus
stimulation point is closest to the root of the ABVN and stimulation would be most
efficient delivered there.

The control condition used was the left earlobe, thought to have little auricular vagus
nerve innervation (81). Aside from the placement, the control stimulation condition
received identical stimulation as the active condition. This condition was included order
to explore the hypothesized non-vagal effects of ear targets. The proximity of the earlobe
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region serves as a very stringent control and used to model the physiological response of
the other nerves in the ear. Subjects were not informed which condition they were getting
or which position was thought to have greater vagal effects.

Safety and Tolerability Reporting
Participants were constantly monitored for major and minor adverse events during each
stimulation session regardless of condition. Major adverse events were categorized as:
extreme decreases in HR (HR) to levels less than 35BPM, respiration difficulty, and
cardiac arrest. Minor adverse events were categorized as: skin discomfort, irritation,
headache, facial pain, and dizziness. Procedurally, stimulation was to be aborted if the
observing personnel noticed any adverse events (this did not occur).

The participant reported pain ratings of each stimulation parameter after each stimulation
block using a numerical rating scale (NRS) ranging from 0-10 after each of the nine
stimulation parameters. “0” was used as the lowest rating for no sensation perceived,
“10” was the highest pain rating for extreme intolerable pain. Participants could use 0.5
increments with a rating of 1 representing the lowest rating where stimulation is felt with
no pain.
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Figure 2-2 Stimulation system and ear targets. a) taVNS was delivered using a FDAcleared constant current stimulator and custom stimulation electrodes. b) Schematic of
left ear demonstrating targets. Active stimulation was delivered to the tragus, control to
the earlobe.
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HR Data Acquisition, Preprocessing, Statistics
Physiological measures were recorded using a 3-channel Thought Technology system
(Thought Technology Ltd), which measured HR using a blood volume pulse (BVP)
sensor worn on the right index finger. BioGraph Infinity Software was used for both
online safety monitoring as well as offline analysis. All HR data was down-sampled to
8Hz and exported to be analyzed in IBM SPSS Statistics version 23 (IBM Corp, USA).

HR was analyzed in 5-second bins. There were 12, 5s bins for stimulation period (totaling
60s); 12, 5s bins for recovery (totaling 60s) and the baseline used was the final 5-seconds
before stimulation started. Change scores for the stimulation period were calculated as
the difference in HR in beats per minute (BPM) during stimulation bin and baseline.
Change scores for the recovery period were calculated from the final stimulation 5second bin (bin 12). All subjects HR was blindly scanned for artifact and all subject data
was included in the analysis (no data removed).

A repeated measures ANOVA was conducted to determine the overall effect of
stimulation condition (active vs. control) on change in HR over time throughout the entire
time course (120s), as well as focused analysis on the stimulation period (60s) and
recovery period (60s) independently. Secondly, individual parametric effects of HR by a
multivariate analysis was conducted. Similar analyses were conducted for the stimulation
and recovery period, and determined partial eta-squared was used to determine effect
sizes.
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Results
Participants, Perceptual Thresholds (PT), and Stimulation Current
15 healthy, right-handed individuals (7 female, 8 male, mean age 26.5 SD 4.99) were
included in this study. All participants completed both visits without any dropouts.
Perceptual thresholds (PT) varied by stimulation site and pulse width. Mean PTs (n=15)
were as follow (mean ± SD mA): 100µs (tragus- 4.64 ± 1.28; earlobe 3.29 ± 0.92) 200µs
(tragus- 2.66 ± 0.80; earlobe 1.82 ± 0.63) 500µs (tragus- 1.5 ± 0.46; earlobe 0.98 ± 0.35).
Using a paired 2-tailed t-test, it was determined that tragus perceptual thresholds were
higher than earlobe perceptual thresholds for each pulse width (p<0.01).

The current at which taVNS was delivered was a scale multiplier of the PT (200%). Mean
stimulation currents were as follow (mean ± SD mA): 100µs (tragus- 9.28 ± 2.56; earlobe
6.57 ± 1.83) 200µs (tragus- 5.32 ± 1.60; earlobe 3.64 ± 1.26) 500µs (tragus- 3.0 ± 0.93;
earlobe 1.97 ± 0.70). Using a paired 2-tailed t-test, it was also determined that tragus
stimulation currents were higher than earlobe perceptual thresholds for each pulse width
(p<0.01). Table 2-1 outlines PTs and stimulation data.

Adverse Events and Pain Ratings
There were no minor or major adverse events during the experimental sessions or
spontaneously reported following exit of the trial. No rapidly accelerated or sustained
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drops in HR were seen during the 1-minute stimulation periods. Minor, temporary light
redness was seen at the sight of stimulation that disappeared within 5 minutes of
stimulation completion.

Parametric NRS scores for pain are described in table 2-2. The lowest rating a participant
could make when they felt stimulation was a 1. For the nine various parameters, as the
pulse width and frequency increased, as did the NRS, although the highest mean tragus
NRS pain rating was 2.133, SD 1.34 (500µs, 25Hz) and the highest mean earlobe NRS
pain rating was 1.23, SD .42 (100µs, 10Hz). Although some of these NRS scale ratings
show statistical significance between stimulation conditions, the behavioral differences of
such low pain ratings are not accurately reflected.
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Table 2-1: Perceptual Threshold and Stimulation Currents for Each Pulse Width Setting.

Pulse
Width

Perceptual Threshold ± SD
(mA)
Tragus
Earlobe
(Active)
(Control)

100µs

4.64 ± 1.28

3.28 ± 0.91

9.28 ± 2.56

6.57 ± 1.83

200µs

2.66 ± 0.80

1.82 ± 0.63

5.32 ± 1.60

3.64 ± 1.26

500µs

1.5 ± 0.47

0.99 ± 0.35

3 ± 0.93

1.97 ± 0.71
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Stim. Current ± SD
(mA)
Tragus
Earlobe
(Active)
(Control)

Significant
(p value)
Y
(p=0.002)
Y
(p=0.003)
Y
(p=0.002)

Table 2-2: Mean NRS Pain Ratings Reported for Each Parameter Tested.

Parameter
1 Hz
100µs
10 Hz
25 Hz
1 Hz
200µs
10 Hz
25 Hz
1 Hz
500µs
10 Hz
25 Hz

Mean NRS Pain Rating ± SD
Tragus
Earlobe
(Active)
(Control)
1.27 ± 0.59
1±0
1.67 ± 0.82
1.23 ± 0.42
1.57 ± 0.82
1.13 ± 0.35
1.27 ± 0.46
1.0 ± 0.0
1.43 ± 0.82
1.03 ± 0.13
2.1 ± 1.36
1.33 ± 1.05
1.2 ± 0.56
1.07 ± 0.26
1.77 ± 0.86
1±0
2.13 ± 1.34
1.17 ± 0.36
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Significant?
(p value)
N
N
N
N
N
N
N
Y (0.004)
Y (0.006)

Overall Effect of Stimulation Condition on HR (HR)
The overall pattern of effect on HR (HR) over time is illustrated in Figure 2-3. taVNS
has very recognizable physiologic signature – when stimulation begins (stimulation
period), HR decreases immediately and is sustained at this lower level. Upon termination
of stimulation (recovery period), there is an immediate reorientation spike in HR that
elevates past baseline for nearly 30 seconds which then regresses back to the mean
resting HR. The nine different stimulation parameters each have a varied effect on HR,
with some inducing large decreases while other parameters are less effective.

To determine the overall effect of taVNS on HR, all active and all control changes in HR
during stimulation were grouped, in 5s bins for a total of 12 consecutive bins. As
demonstrated in figure 2-4, when all parameters are grouped together, both active
(tragus) and control (earlobe) stimulation have a bradycardia effect, with an active mean
HR decrease from baseline of 1.43 beats per minute (BPM), SEM 0.20, and control mean
HR decrease of 1.02, SEM 0.20. In a repeated measures ANOVA statistical comparison,
this effect was not significant.

A repeated measures ANOVA was conducted on the one-minute post-stimulation period
change in HR (from the final 5 second bin of stimulation). The sympathetic rebound that
occurs upon termination of taVNS was blunted by active stimulation compared to control
demonstrating a condition effect of rebound spike (p<0.001).
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Active

Stimulation Period (ON)

Stimulation Period (OFF)

Control
Figure 2-3 Overview of mean HR changes over time for all 9 parameters. This figure
presents the effect of both active and control stimulation on heart rate. Stimulation seems
to have an immediate bradycardia effect during stimulation, followed by a tachycardia
rebound when stimulation is turned off.

46

Figure 2-4 Mean change in HR over time (active v control). This figure presents the
mean change of all 9 parameters tested in this trial, revealing a decrease in HR during
stimulation and a recovery heart rate spike upon termination. Overall time course analysis
reveals an overall effect of condition (P<0.001). There was non-significant effects of
condition on the stimulation-induced bradycardia. Active stimulation had a significantly
lower recovery heart rate spike (P<0.001).
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The peak HR rebound was achieved during the third 5-second bin (15 seconds posttaVNS) with a max rebound in HR for active taVNS of 8.153BPM and control
stimulation of 11.361 BPM. The sympathetic spike time-course analysis revealed a
significant condition*time interaction (p<0.001), as active stimulation returns to baseline
much quicker than control stimulation.

Multivariate Analysis of HR to Determine Parametric Effects
The grouped data can subsequently be split based on specific parameters in a multivariate
analysis. Some parameters were hypothesized to have a biologic effect whereas others
were not. Table 2-3 shows the mean effects on HR during the stimulation period,
separated by individual parameters. Several parameters were determined to have an effect
of condition on the decrease of HR in the stimulation period. There were two parameters
that had large, significant effects by condition in which active stimulation decreased HR
more than control stimulation, and in which there was no decrease in HR in the control
condition. These were 500µs, 25Hz (active HR -3.13BPM, control 0.799, p<0.001) and
500µs, 10Hz (Active HR -.929 BPM, control .290, p=0.01). The HR trace during
stimulation for these two parameters is presented in Figure 2-5.

A multivariate analysis was also performed on the sympathetic reorientation spike in HR.
Several parameters were demonstrated to suppress this sympathetic spike during the
recovery period. These data are demonstrated in Table 2-4. The optimal parameter for
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Table 2-3: Multivariate Analysis of Mean Change in HR from Baseline

Parameter
1 Hz
100µs
10 Hz
25 Hz
1 Hz
200µs
10 Hz
25 Hz
1 Hz
500µs
10 Hz
25 Hz

Mean Change in HR from Baseline ±
SEM
(Average over 60s Stimulation Period)
Tragus
Earlobe
(Active)
(Control)
-0.744 ± .781
-2.40 ± .781
-1.17 ± .0.461
-0.891 ± 0.461
0.24 ± 0.362
0.524 ± 0.362
0.07 ± 0.631
-2.01 ± 0.631
-1.54 ± 0.353
-2.86 ± 0.353
-3.57 ± 0.436
-1.81 ± 0.436
-2.17 ± 0.337
-0.857 ± 0.337
-0.93 ± 0.335
0.290 ± 0.335
-3.13 ± 0.545
0.799 ± 0.545
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Partial
Eta Sq.
0.007
0.001
0.001
0.016
0.021
0.024
0.022
0.019
0.072

Condition
Effect?
(p value)
N
N
N
Y (0.008)
Y (0.005)
Y (0.006)
Y (0.006)
Y (0.01)
Y (<0.001)

Figure 2-5 Parameters with largest bradycardia effect during stimulation. Active
taVNS had significant parasympathetic activation compared to control in the following
parameters (500us, 10Hz; 500us, 25Hz).
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Table 2-4: Multivariate Analysis on Mean Change in HR for Recovery Period

Parameter
1 Hz
100µs 10 Hz
25 Hz
1 Hz
200µs 10 Hz
25 Hz
1 Hz
500µs 10 Hz
25 Hz

Mean Change in Recovery HR ± SD
(Average over 60s Recovery Period)
Tragus
Earlobe
(Active)
(Control)
3.859 ± 0.998
7.296 ± 0.998
1.244 ± 0.547
4.077 ± 0.547
4.348 ± 0.581
5.2 ± 0.581
5.436 ± 0.672
5.76 ± 0.672
3.591 ± 0.476
4.59 ± 0.476
2.995 ± 0.600
5.792 ± 0.600
4.512 ± 00.647
5.755 ± 00.647
2.703 ± 0.539
4.926 ± 0.539
2.644 ± 0.601
5.474 ± 0.601
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Partial
Eta Sq.
0.017
0.038
0.003
0.000
0.007
0.031
0.005
0.025
0.032

Condition
Effect?
(p value)
Y (0.015)
Y (<0.001)
N
N
N
Y (0.001)
N
Y (0.004)
Y (0.006)

suppression of the parasympathetic rebound based on magnitude difference of peak spike
suppression was 100µs, 10Hz and 500µs 10Hz.

Discussion
Our analysis reveal that one-minute stimulation sessions of the left tragus is a safe form
of neuromodulation that has no major or significant acute bradycardia effect during the
stimulation period compared to control, although active taVNS suppresses the poststimulation tachycardia rebound associated with sympathetic recovery. When
multivariate analyses were conducted, significant parameter-specific bradycardia effects
and tachycardia suppression during and post stimulation were revealed. Conditions with
more energy dense parameters had noticeably larger effects. Most notably, the parameters
with highest bradycardia effects were those with higher pulse width and frequency
(500µs 10Hz and 500µs 25Hz). The largest suppressors of the sympathetic rebound in
HR post-stimulation were ones with 10Hz frequency (500µs, 10Hz; 100µs,10Hz)

We enrolled 15 healthy individuals in this parametric feasibility and safety trial exploring
the effects of nine various taVNS parameters of different frequencies and pulse widths.
To our knowledge, this is the first prospective trial to systematically test the physiological
effects of various taVNS parameters. From a feasibility and safety perspective, a taVNS
system with custom electrodes was built for conducting laboratory studies. There were no
minor or major adverse effects observed throughout the duration of this trial, suggesting 1
minute taVNS periods at 200% perceptual threshold is safe and tolerable. This is very
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similar to the safety of cervically implanted VNS (27, 33). We also determined that
sensitivity based on perceptual thresholds varied by pulse width and stimulation location.
As pulse width increases, less current is needed for the sensation to be perceived. The
earlobe is significantly more sensitive (needs more current) than the tragus. The mean
overall pain scores for active taVNS were recorded as 1.6 versus control stimulation of
1.1. These are considered perceivable but not painful, making taVNS rather painless.

Like all neuromodulation methods, the parameter space is vast and systematic parametric
optimization trials are needed to determine optimal stimulation parameters. This trial
suggests that individual parameters may be better than others at modulating vagal tone as
measured by HR. Although there was no condition effect when all parameters were
combined, there were clearly parameters that induced significant bradycardia associated
with the parasympathetic nervous system, which is directly modulated by the vagus nerve
(10). The more energy dense parameters caused larger decreases in HR compared to the
lower frequency or smaller pulse width parameters. It is early to make a conclusion as to
whether these effects are directly driven through the vagus nerve, although given the
strict control region, these data are very encouraging.

The sympathetic rebound attenuation was an unexpected finding. It has been
demonstrated in the prior studies that this sympathetic spike in HR occurs after
stimuli(109, 110) and is thought to be a reorienting phenomenon. It is seen
pharmacologically as well, demonstrated in a reciprocal effect of noradrenergic blockade
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via beta-blockers (111). The reciprocal mechanisms are intended to maintain bodily
homeostasis and rapid activation/deactivation of stimulation of either system has a strong
reciprocal action that occurs afterwards. This effect was measured temporally, lasting
approximately 15 seconds to peak sympathetic rebound and final recovery to baseline at
1minute. One prior taVNS trial suggests sympathetic nervous activity is reduced upon
stimulation (86). It was not anticipated that active taVNS may be able to significantly
attenuate this sympathetic rebound and it may be due to a sustained parasympathetic
effect that persists beyond stimulation.

There is a dose confound revealed in these findings, as the PT for active and control sites
were significantly different for each of the three pulse width settings. This occurred as a
product of trying to control for stimulation pain levels by conducting a titration based on
sensory perception. If we had controlled for stimulation current (i.e. given everyone
identical stimulation parameters) we would have likely seen a confound of painfulness.
Whether the current strength that is driving the condition effect rather than the pulse
width or frequency is still unknown, but should be acknowledged as a limitation of this
trial.

There have been several studies exploring the behavioral effects of taVNS, many of
which are positive (78, 83, 112, 113) and prior literature has suggested that tragus
stimulation directly modulates the vagus network via the ABVN. There have also been
recent studies demonstrating stimulation of the ABCN has a direct effect on the afferent
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projection of the vagus nerve, with similarities in blood oxygen level dependent (BOLD)
as compared to cervically implanted VNS (91, 92). These fMRI findings suggest one
possible mechanistic hypothesis for the immediate, sustained decrease in HR –
stimulation is entering the afferent vagus system towards the central nervous system,
activating the parasympathetic efferent cholinergic pathway targeting the viscera,
including the heart.

This field is still in its infancy and there is a lack of consensus on parameters. There is a
wide range of currents (ranging from sub-perceptual threshold to sub-painful threshold),
frequency (ranging from 1Hz to 299Hz), pulse width (ranging from 20us-1ms)
stimulation duration (ranging from brief pulses to 1 minute), and type of electrical
stimulation (constant current/voltage/direct/alternating) (91, 92, 104-108, 112). It would
be impossible to test all various parameters, but many groups have leaned on the
parameters used in cervically implanted VNS as a guideline.

This study aimed to guide future taVNS trials in safety and HR effect of these
parameters. It is important to determine stimulation current based on individual
perceptual threshold, although it is still unknown as to what level (sub- or suprathreshold stimulation) works best. It is plausible to suggest a pulse width closer to
chronaxie (approximately 500µs) (35) would optimally cause depolarization of nerves
and shrink the wide range of potential parameters. And lastly, it is important to use a
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stringent control region on the same ear of stimulation, since there appears to be a large
physiological response due to ear lobe stimulation alone.

Limitations
We acknowledge that a sample size of 15 individuals may not be large enough to truly
determine which parameters modulate HR the best. This initial trial was developed as a
safety and feasibility trial, with the secondary effects of HR to be explored, as the
parameter space was quite large. Larger controlled trials should further explore some of
the parameters here that are suggested to be more optimal in modulating HR.

Secondly, it is impossible to truly say these outcomes are as a direct effect of stimulating
the ABVN as the only way to definitively say that would require dissection and direct
nerve stimulation. Based on prior literature and anatomical trials (81), we believe that
stimulation of the tragus is directly stimulating the ABVN, whereas the earlobe has little
to no ABVN innervation, and therefore less parasympathetic derived effects.

Lastly, we concede it is still unknown whether the effects seen are through the
hypothesized afferent central targets of the vagus system (ear –> brain –> vagus -> body),
or whether they are modulating parasympathetic response via direct efferent projections
from the ear to the periphery (ear -> vagus -> heart). This is difficult to determine without
systematic, parametric testing using combined taVNS and neuroimaging paradigms or
with in-vivo microelectrode recording of nerve dissections in animal models.
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Conclusion
taVNS administered for 1 minute at 200% perceptual threshold in these nine parameters
is a feasible and safe neuromodulator technique. No significant adverse events were
observed and overall, both active and control stimulation result in a minor bradycardia
during stimulation, whereas active stimulation suppressed the sympathetic reciprocal
effect post-stimulation. Further parametric exploration must be conducted to determine
optimal taVNS parameters.
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CHAPTER 3
STUDY 2: DETERMINING THE OPTIMAL taVNS PARAMTER WHICH
ACTIVATES THE PARASYMPATHETIC NERVOUS SYSTEM

Study Summary
Background: An initial exploratory study conducted by our team (described in Chapter
2) investigated the effects of nine various taVNS parameters on HR and determined two
optimal parameters which most likely activated the parasympathetic nervous system. This
study follows-up on this initial trial by testing the winning parameters against each other
and against control.

Objective: Determine which of the following parameters (500µs 10Hz or 500µs 25Hz)
optimally activate the parasympathetic nervous system compared to control stimulation.

Methods: We enrolled 20 healthy individuals in a 2-visit follow-up trial exploring the
HR effects of the two parameters optimally modulating HR determined by trial 1.
Individuals attended two separate experimental visits (active, control) and received 10
sessions of 1-minute taVNS, flanked by a 60 second baseline and 90 second recovery
period. HR was monitored continually throughout each experimental visit. Statistical
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analysis was conducted on overall effect of condition (both parameters combined; active
vs control) for the entire time course (120s) as well as a focused analysis on the
independent stimulation period (60s) and recovery period (60s). Specific parametric
analysis on each discrete parameter was conducted exploring the overall individual
parameter effects (active vs control) similar to the method for all paramters.

Results: Active taVNS significantly decreased HR compared to control during
stimulation (p=0.02). taVNS did not affect recovery sympathetic spikes as control and
active stimulation had similar magnitude reorientation increases in HR. The overall effect
was primarily driven by the strong bradycardia effect induced in the 500µs 10Hz
parameter (p=0.032) although both active parameters decreased HR compared to control.

Conclusion: This confirmatory follow-up study determined that the optimal parameter to
modulate the parasympathetic response activated via direct electrical stimulation of the
auricular branch of the vagus nerve (ABVN) was 500µs, 10Hz. Both active parameters
induced bradycardia compared to control, suggesting taVNS activates the
parasympathetic nervous system.

Introduction
Study Aim 1 Findings
Chapter 2 of this dissertation described an initial parametric study we conducted in 15
healthy individuals. The goal of this first trial was three-fold. Initially, when developing a
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novel form of neuromodulation, it is important to establish the safety profile of the
method, as well as appease concerns of the MUSC IRB concerning participant safety. In
2014 when these trials were conceptually started, the literature was very sparse and
MUSC had not conducted a prior taVNS study. There also was no system to administer
it, so Bashar Badran (with the help of Alan Badran) developed stimulating electrodes
targeting the requisite ear targets.

Secondly, the trial was aimed at determining whether there were parameter-specific
effects of taVNS on HR. More precisely, we aimed to determine whether longer pulse
widths and higher frequencies (more energy per pulse) would result in larger decreases in
HR via the parasympathetic nervous system. Prior cervically implanted VNS/fMRI trials
conducted by Nahas et al (51) demonstrated increased blood oxygen level dependent
(BOLD) signal activation in the brain as the pulse width was serially increased from
130us to 500us. Before conducting studies in the MRI scanner with our taVNS system,
we aimed to use HR as a surrogate marker of parasympathetic activity and show
increased effects with higher pulse widths and frequencies.

Our final goal was to determine which of the nine parameters were optimal in modulating
the parasympathetic system. We analyzed this data and compiled the measures to give us
an overall perspective on optimal parameters. The effect size of the repeated measures
ANOVA as well as whether there was a control effect were both unutilized in making the
ultimate decision that 500us 10Hz and 500us 25Hz parameters optimal parameters at
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modulating parasympathetic nervous system activity. The findings of the first study
determined that taVNS was feasible, safe, and identified optimal parameters of the initial
nine exploratory parameters.

Rationale Behind Study 2
This follow-up study aimed to be a confirmatory study on the parameters hypothesized to
optimally modulate the parasympathetic nervous system. To do this, the best two
parameters from study 1 (500µs 10Hz & 500µs 25Hz) were tested against each other and
against control stimulation (earlobe). To positively determine this, the number of
participants was increased to 20 for this follow-up trial and also increased the number of
times the parameter was tested (five stimulation runs for each parameter, 10 total), unlike
trial 1 which had only one stimulation run for each of the 9 parameters. We hypothesized
that by making these changes, active taVNS will have a significant effect on HR during
stimulation. More specifically active taVNS will induce bradycardia during stimulation
as modulated by the parasympathetic nervous system activation that occurs. Given the
nerve innervation of the human auricle (81), control stimulation should have minimal
effect on activating the parasympathetic nervous system.
Methods
Overview
This follow-up study is resembles and is nearly identical to the design of the first HR
study described in Chapter 2. This study conducted was a 2-visit, controlled, crossover
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trial. Individuals came to the Medical University of South Carolina (MUSC) brain
stimulation laboratory for two separate 45 minute experimental visits (active/control
visits, counterbalanced design) (Figure 3-1a). Each visit was identical except for
stimulation condition. This study was approved by the MUSC Institutional Review Board
(IRB) and is registered on ClinicalTrials.org (NCT02835885).

Although similar to the study described in Chapter 2, there are several important major
changes that differentiate this study from the prior study. The reader should draw their
attention to the following differences:

1.

Only 2 parameters are explored in this trial (500us 10Hz, 500us, 25Hz).
See introduction for the rationale.

2.

10 stimulation rounds were administered each visit (5 for each parameter).
This differs from study 1 in which each parameter was tested only once.
This is intended to increase the power for statistical analysis.

3.

Biopac System was used for Heart Rate using 2-channel
electrocardiogram (ECG) rather than BVP as used in the Thought
Technology system from study 1.

4.

Methods that are repeated in this section will be indicated to refer reader
back to the appropriate section of Chapter 2 to avoid repeating general
methodology.
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Participants and Inclusion Criteria
We enrolled 20 healthy adults (10 female) in this trial after meeting the same inclusion
criteria listed in Chapter 2 (See Chapter 2, Methods for detailed description).

taVNS Stimulation System
We used the same stimulation system developed for the initial HR study described in the
previous chapter. (See Chapter 2, Methods for detailed description and figure.)

taVNS Stimulation Paradigm & Parameters
Participants lay supine with their neck and head elevated in a comfortable position with a
pillow. They were instructed to stay awake and maintain a still, comfortable position.
Stimulation targets were prepped with alcohol swabs (70% isopropyl alcohol) to clean
surface oils and decrease skin resistance.

Stimulation parameters of either 500µs 10Hz or 500µs 25Hz were used. Parameters were
randomized and counterbalanced over each of the 10 rounds (5 rounds of each
parameter). These parameters were chosen as the most likely candidates to best modulate
heart rate from trial 1. Similarly to trial 1, the stimulation current (mA) was delivered at
200% of each participant’s individual perceptual threshold (PT) of a 500µs pulse width.
Each stimulation period lasted 1minute, flanked by a 60 second baseline and 90s recovery
period. This is repeated 10 times, once for each stimulation parameter in a randomized
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Figure 3-1 Overview of Study a) timeline demonstrating flow of participants through
trial. b) Experimental visit timeline. Each participant attended two identical visits
structured as presented in the figure.
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order between subjects (orders were kept identical within both subject visits). See Figure
3-1b for an overview of experimental design.

Ear Stimulation Targets
This controlled trial employed identical stimulation sites on the left ear. Active taVNS
was delivered to the left tragus, control stimulation to the left earlobe. For a detailed
description and figure of these sites, refer to Chapter 2, Methods, Ear Stimulation
Targets).

Safety and Tolerability Reporting
Participants were constantly monitored for major and minor adverse events during each
stimulation session regardless of condition and were asked to report pain ratings at the
completion of each of the ten stimulation periods using a NRS. For a detailed description
of safety criteria and NRS refer to Chapter 2, Methods).

HR Data Acquisition, Preprocessing, Statistics
Physiological measures were recorded using a 2-channel Biopac ECG system (Biopac
Systems Inc., USA), which measured HR using electrocardiogram electrodes attached to
the subject’s chest. AcqKnowledge 4.1 software was used for both online safety
monitoring as well as offline analysis. All HR was consolidated into 5sec epoch bins and
exported for analysis in IBM SPSS Statistics version 23 (IBM Corp, USA).
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HR was scanned for usability, and participant 20 of this study reported excessive artifact
in stimulation round C of the control visit, which was excluded from analysis. The
remaining 9 stimulation rounds for this participant were kept in the analysis.

HR was analyzed in 5-second bins. There were 12 bins for stimulation period (totaling
60s); 12 bins for recovery (totaling 60s). The baseline used was the final 5-seconds
before stimulation started. Change scores for the stimulation period were calculated as
the difference in HR in beats per minute (BPM) during stimulation bin and baseline.
Change scores for the recovery period were calculated from the final stimulation 5second bin (bin 12).

A repeated measures ANOVA was conducted to determine the overall effect of
stimulation condition (active vs. control) on change in HR over time throughout the entire
time course (120s), as well as focused analysis on the stimulation period (60s) and
recovery period (60s) independently. Secondly, individual parametric effects of HR by a
multivariate analysis was conducted. Similar analyses were conducted for the stimulation
and recovery period, and determined partial eta-squared was used to determine effect
sizes.
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Results
Participants, Perceptual Thresholds (PT), and Stimulation Current
20 healthy, right-handed individuals (10 female, 10 male, mean age 25.65 SD 5.53) were
included in this study. All participants completed both visits without any dropouts. Mean
perceptual thresholds (PT) are as follow (mean ± SD mA): 500µs (tragus- 1.045 ± 0.49;
earlobe 1.02 ± 0.41). The current at which taVNS was delivered was again a scale
multiplier of the PT (200%). Mean stimulation currents were as follow (mean ± SD mA):
500µs (tragus- 2.09 ± 0.97; earlobe 2.04 ± 0.82). Using a paired 2-tailed t-test, it was
determined that there was no difference in perceptual threshold between the two
stimulation sites. Table 1 outlines mean PTs and stimulation data for all subjects.

Adverse Events and Pain Ratings
Similar to experiment one, there were no minor or major adverse events during
experiment two. The Mean NRS scores for pain are described in table 3-1, and although
there was a significant difference in pain between parametric-specific stimulation targets
when analyzed using a paired t-test, these are not reflective of the minimal pain reflected
in the ratings (mean pain difference between conditions less than one rating point, max
mean rating 2.24). These pain ratings should be considered relatively painless for both
conditions.
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Effect of Stimulation Condition on HR (HR)
Experiment two successfully demonstrated replication of the physiological response to
taVNS. As stimulation starts, there is an immediate bradycardia observed that persists
throughout the entire stimulation period. Upon termination of stimulation tachycardia
occurs for approximately 30s. The overall effect on HR over the 120-second period is not
statistically significant. Figure 3-2 shows the time course analysis of mean changes from
baseline in the stimulation and recovery periods of all active vs. all control stimulation
rounds.

To determine the effect of taVNS on HR during the stimulation period, the 60s
stimulation period was analyzed by condition in a repeated measures ANOVA and
demonstrates a strong active taVNS effect on bradycardia (P<0.02). Active taVNS
produced a mean decrease in HR of 1.82 ± 0.174 (SD), whereas control stimulation only
decreased a mean of 1.2BPM ± 0.178 (SD). A repeated measures ANOVA was also
conducted on the recovery period, which did not meet significance.
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Table 3-1: Mean PT, Stimulation Current, and Pain NRS ratings

PT ± SD (mA)
Stim. Current ±
SD (mA)
Mean 500us 10Hz
NRS Pain Rating
± SD
Mean 500us 25Hz
NRS Pain Rating
± SD

Tragus
(Active)

Earlobe
(Control)

1.045 ± 0.48

1.02 ± 0.41

2.09 ± 0.97

2.04 ± 0.82

1.35 ± 0.68

2.24 ± 1.28

Y (P<0.01)

1.32 ± 0.57

2.10 ± 1.17

Y (P<0.01)

69

Significant?
(p value)
N

Figure 3-2 Mean change in HR over time (active v control). This figure presents the
mean change of all both parameters tested in this trial. Active taVNS induces significant
decrease in HR during stimulation (p=0.02), although the recovery HR spike upon
termination is not significantly different from control.
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Parameter-Specific Effects on HR
The grouped data can subsequently be split into 500µs, 10Hz and 500µs 25Hz
parameters. Exploring the significant effect of bradycardia in the stimulation period in the
overall analysis, a repeated measures ANOVA was conducted on the stimulation period
by parameter, and the results are highlighted in Figure 3-3. Active taVNS at 500µs, 10Hz
induces a significant bradycardia effect sustained throughout the entire stimulation period
(P=0.032). Mean decrease for the active condition was -2.40BPM ± 0.275 vs. control,
which only produced a -1.56BPM ± 0.275 change from baseline (Table 3-2). The 500µs
25Hz parameter showed a non-significant effect on bradycardia throughout the
stimulation period.

Discussion
We enrolled 20 healthy individuals in this follow-up, confirmatory study aimed to
determine the optimal taVNS parameter modulating parasympathetic nervous system
activity. When compared against control stimulation, active taVNS significantly
decreased HR, a surrogate marker of parasympathetic nervous system activity. When
analyzed by parameter, 500µs 10Hz had the greatest effect on HR during the stimulation
period. A prior taVNS trial suggested sympathetic nervous activity is reduced upon
stimulation (86) and is briefly mentioned in Chapter 2. That study used a smaller pulse
width, but higher frequency (200µs 30Hz). Whether the mechanism is the direct decrease
of sympathetic system or rather the increase of the parasympathetic nervous system is
still unknown.
71

a

Overall Bradycardia Effect

b
500us, 10Hz bradycardia
effect

c
500us, 25Hz bradycardia
effect

Figure 3-3
Figure 3-3 Parametric effects on bradycardia. a) Overall effect of active taVNS
compared to control (p=0.02). b-c) Active taVNS at 500us 10Hz has a significant effect
on HR (p=0.032) when compared to control whereas 500us 25Hz is not statistically
different.
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Table 3-2: Mean Decrease in HR During Stimulation Period (By Parameter)

Parameter
10 Hz
500µs
25 Hz

Mean Change in HR from Baseline ±
SEM
(Average over 60s Stimulation Period)
Tragus
Earlobe
(Active)
(Control)
-2.40 ± 0.275.
-1.56 ± 0.275
-1.244 ± .180

-1.036 ± 1.84
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Partial
Eta Sq.
0.01
0.001

Condition
Effect?
(p value)
Y
(P=0.032)
N

Unlike the initial nine-parameter trial described in Chapter 2, which demonstrated an
attenuation of the sympathetic rebound in HR in the recovery period, this effect was not
demonstrated in this study in either the overall or parametric study analysis. Both active
and control stimulations had similar spikes in HR upon termination of stimulation that
occurs as a described in the healthy functioning of the autonomic nervous system(109,
110). It is suspected that the reciprocal sympathetic spike in heart rate counteracts the
parasympathetic activation via active taVNS, although in this trial, the active stimulation
effect was much larger than the first trial, possibly causing a higher magnitude reciprocal
spike. This directly contradicts the initial hypothesis generated from Study 1 in which it
was believed there was a persisting parasympathetic activation that blunts the
sympathetic spike. It is impossible to say that this is definitively what is occurring and
future studies should be designed to directly focus on this balance between rapid
sympathetic/parasympathetic activation.

The many trials exploring the positive neuropsychiatric effects of taVNS (78, 83, 112,
113) could not possible if taVNS had primarily an efferent parasympathetic effect. It
must be due to increasing parasympathetic or decreasing sympathetic nervous system
activity as modulated centrally in either cortical or subcortical brain structure. Recent
fMRI trials seem to confirm this hypothesis (91, 92). One can reasonably conclude that
taVNS has both afferent and efferent vagal effects although whether the modulation of
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heart rate is directly efferent or whether the heart rate effect is due to a short loop traveled
by the signal to the central hypothalamic cholinergic pathway is still to be determined.

It is unknown as to which is more important – pulse width or frequency. There is a
lacking of data in the recent taVNS trials to answer such a question. The various
behavioral effects are derived from many various pulse widths, frequencies and
stimulation currents. (91, 92, 104-108, 112). This trial confirms that a pulse width of
500µs at both 10Hz and 25Hz, when combined, give an overall effect of bradycardia
during stimulation and that the 10Hz parameter, when compared to control, induced a
larger effect on HR. It is suspected that pulse width is more important than firing
frequency, as that is required for neuronal depolarization near the nerve chronaxie levels
(35) causing depolarization and signal transduction.

The bradycardia associated with control stimulation was again seen in this study,
similarly in effect and magnitude to trial 1. A responsive control site is important to
investigate the active site of stimulation with rigor, although it is plausible that there may
be some transduction of electrical signal into superficial branches of the ABVN. Nerves
are often branched and act as electrical conductors. It is highly plausible that there is
some transduction of electricity from the earlobe to distal branches of the ABVN that
may be spatially proximal to the site of stimulation. Even with stringent controls, the
parasympathetic effect of taVNS is significant, demonstrating that less than 3 cm of
distance can have different physiological effects on the human.
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Conclusion
This follow-up study confirms that electrical stimulation of the a ABVN via taVNS at
500µs 10Hz is the optimal parameter for activating the parasympathetic nervous system
and decreasing heart rate in healthy individuals. No significant adverse events were
observed and overall. Active taVNS in an overall analysis demonstrated significant
bradycardia during the stimulation period. This serves as a strong foundation that
stimulation of the ABVN can induce efferent autonomic nervous system responses that
can be measured using physiological recordings. It is important to conduct neuroimaging
trails further exploring the central effect of taVNS to determine whether there are
significant brain activations associated that maybe independent or driving these
parasympathetic effects.

Synthesis of Experiments One and Two
The two prior experiments described are important both practically and conceptually.
There is an ever-present push to drive therapeutics rapidly towards treating various
disorders, whether central or peripheral. This rush introduces a high risk of failure, or the
early dismissal of a therapy that may have a biologic effect if parametrically tested for
optimal administration.

In the case of electrical stimulation, there are a variety of different parameter
combinations that may have a biologic effect. This series of studies demonstrates 1) pulse
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width matters. The higher the pulse width, the stronger of an effect described in the initial
parametric trial. 2) Higher frequencies are not always better. 10Hz outperformed 25Hz in
the follow-up confirmatory trial. 3) taVNS does have a biologic effect that seems to be
driven through the vagus nerve.

The final confirmatory step to determine if taVNS has a direct brain effect or whether
these are just peripheral vagal responses is to conduct a concurrent taVNS imaging trial
exploring the brains response to stimulation. This was the third aim of the dissertation
and will be presented in the subsequent chapter.
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CHAPTER 4
STUDY 3: USING CONCURRENT taVNS/fMRI TO DETERMINE THE DIRECT
BRAIN EFFECTS of taVNS
Study Summary
Background: Although there are numerous trials involving stimulating the auricular
branch of the vagus nerve (ABVN), the exact brain regions activated are poorly
understood. Electrical stimulation of the ABVN via transcutaneous auricular vagus nerve
stimulation (taVNS) likely targets vagal afferent networks and is the theorized
mechanism for taVNS.

Objective: We developed a concurrent taVNS/fMRI system to determine the direct brain
effects of taVNS compared against control stimulation.

Methods: We enrolled 17 individuals in the two-visit controlled, crossover trial.
Individuals attended two scanning visits in which they received taVNS at 500µs 25HZ
delivered to either their left earlobe (control) or tragus (active). Whole brain analysis was
performed using SPM 12 exploring the effect of the following groups: control stimulation
only, active stimulation only, active>control, active <control (FWE corrected P<0.05).
An ROI analysis was conducted on the midbrain and brainstem regions of all groups.
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Results: Earlobe (control) stimulation produces BOLD signal activation in the
contralateral somatosensory representation of the face region, whereas tragus (active)
stimulation produces significant activations in the contralateral postcentral gyrus,
bilateral insula, frontal cortex, right operculum, and left cerebellum. In the active vs.
control contrast, active stimulation produces significant activations in the right caudate,
bilateral anterior cingulate, cerebellum, left prefrontal cortex, and mid-cingulate.

Conclusion: These findings reveal the afferent projection of taVNS delivered to the
tragus produces cortical and subcortical effects in regions of the brain known to be part of
the afferent vagal pathway.

Introduction
Modern functional neuroimaging methods can be used to measure the neurophysiological
effects of a stimulus or intervention. The most common of these methods are
electroencephalography (EEG), positron emission tomography (PET), and functional
magnetic imaging (fMRI). Each technique has its benefits and drawbacks. EEG has an
extremely high temporal resolution on the scale of milliseconds and is great for capturing
fast neuronal propagations, although it lacks spatial resolution and deductions can only
reliably be made regarding cortical activity. PET and fMRI are similar as they both
indirectly measure brain activity, although PET has a much lower imaging resolution
than fMRI, uses radioactive isotopes, and is more expensive.
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fMRI images the blood oxygen level dependent (BOLD) signal in the brain, which is
considered and utilized as an indirect marker of neural activity (47). The BOLD signal
measures the temporal changes of oxyhemoglobin and deoxyhemoglobin. As neuronal
depolarization occurs, oxygen is consumed and increased blood flow is delivered to
higher metabolism areas, bringing with it oxyhemoglobin, producing a stronger MR
signal than its deoxygenated counterpart. It is this difference in magnetism is exploited in
the fMRI method. In short, increased oxyhemoglobin is believed to reflect increased
neuronal activation.

taVNS/fMRI Potential Roadblocks and Solutions
In order to successfully conduct these multimodal imaging trials in which stimulation
electrodes like those used in cervically implanted VNS and taVNS and conductive wires
are either implanted or externally placed in the magnetic field of the scanner, the
following potential issues need to be considered:

1. Induced electrical current in the wire
In 1831, Michael Faraday (114) demonstrated the law of induction. Faraday’s law states
that electrical current is produced in conductive materials placed in or around a magnetic
field. Electromagnetic induction is used in power generation and transmission and is used
immensely in modern electronics. We also can reference Faraday’s law for how
transcranial magnetic stimulation (TMS) works (115) in stimulating the brain.
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Unfortunately, induction poses a problem when placing conductive materials in the MRI
scanner. The static and dynamic magnetic field of the scanner introduces the risk of
inducing unwanted electrical current in the wire.

To circumvent these induced fields, resistors (5kΩ) of sufficient size must be placed in
the lead wires of the electrode to block these currents while simultaneously being able to
be surmounted by the power of the driving electrical stimulator. Without controlling for
induced currents, unwanted stimulation of target sites may occur without intent or
knowledge.

2. Electrode Heating
A potential safety concern of electrodes attached to the end of long wires placed in the
MRI is the risk of heating these electrodes due to the interaction of the radio frequency
(RF) electromagnetic field (116-119). This heating occurs at the end of the wire or
electrode and can cause burns to the stimulation site, or even permanent irreversible
damage if the electrodes are implanted in the case of VNS or deep brain stimulation
(DBS) (49, 120). For this reason, sufficient testing must be conducted to determine safety
of these paradigms.

Although there is no direct solution to this problem, special head coils for the fMRI
image acquisition can be used in order to minimize the RF electromagnetic field and
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minimize heating. The resistors placed in the lead wires also reduce the heating. It is
important to ensure the conductive medium (e.g. gel, paste) used for stimulation can
withstand heating without degrading.

3. MRI Artifact
Wires delivering electrical stimulation from outside the magnet room of the scanner
(equipment room or control room) introduce RF into the scanner. The wire becomes a
large antenna that may produce an RF overflow artifact causing a non-uniform
appearance in part of the image or even the entire image. In order to minimize this
artifact issue, any externally driven stimulation needs to be delivered through an RF filter
and grounded to a panel so that the fMRI signal does not become distorted.

The prior three concerns were all addressed before conducting the final study described
in this chapter. All developmental experimentation was conducted on MRI phantoms in
order to optimize stimulation feasibility as well as reduce artifact and heating and ensures
safety. Three pilot scans on healthy individuals were also conducted following phantom
trials, those individuals were used for optimization of the taVNS method and were not
enrolled into the prospective taVNS/fMRI trial.

Prior taVNS/fMRI Trials
There have been five imaging trials specifically designed to determine the afferent
pathway of taVNS. The first taVNS/fMRI trial was conducted in 2007 by Kraus and
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colleagues (91). They used fMRI to image 22 healthy individuals and aimed to determine
whether stimulating the left tragus (active) or earlobe (control) at 20µs and 8 Hz for (30s
ON, 60s OFF) produced short-term brain activations in a crossover design. Active
stimulation produced decreases in limbic brain areas, including the amygdala,
hippocampus, parahippocampal gyrus and the middle and superior temporal gyrus. They
also demonstrated increased activation in the insula, precentral gyrus and the
thalamus. Control stimulation revealed no significant BOLD responses in either direction.
No brainstem activation was reported in either condition.

This same group conducted a follow-up trial in 16 healthy individuals exploring regional
specificity of the induced BOLD response from taVNS. This study stimulated either the
left auditory canal (8 subjects receiving anterior tragus stimulation, 8 subjects receiving
posterior auditory ear canal stimulation) or the earlobe (all 16 subjects) in a crossover
design. Stimulation parameters were identical to their prior trial (20µs and 8 Hz for 30s
ON, 60s OFF). The results of the study are in line with their previous fMRI studies (92),
showing robust BOLD signal decreases in limbic structures and the brain stem during as
well as BOLD activation in frontal and insular cortex via electrical stimulation of the left
anterior auditory canal. Interestingly, stimulation at the posterior wall seems to lead to
unspecific changes of the BOLD signal within the brainstem and vagal afferent
projections. Earlobe control stimulation again produced no major significant BOLD
signal responses. This study suggests the anterior auditory canal (tragus) to be a much
more effective ABVN target than the posterior wall.
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In 2008, a very small taVNS trial was conducted by Dietrich and colleagues in four
healthy males. The goal of this study was to test new parameter settings and a novel
device they have developed. This open-label single arm (active only) study delivered 50s
blocks of taVNS (250µs, 25HZ) to the left tragus. They authors suggest that taVNS
induced increases in BOLD signal in the thalamus, prefrontal cortex and brainstem (90)
although this was not described in any of the other four trials. This study is considered
very inconclusive as it lacks effective control and based on the small sample size, but
merits further exploration of the parameters employed.

In 2015, Frangos et al (93) conducted a taVNS/fMRI trial exploring the regional effects
of electrical stimulation of two stimulation sites (cymba conchae vs. earlobe control;
crossover design) in 12 healthy individuals. The stimulation parameters were 250µs,
25Hz, for one stimulation ON block lasting 7minutes. Their findings reveal conchae
stimulation, compared to earlobe (control) stimulation, produced significant activation of
vagal afferents, most notably the ipsilateral NTS, locus coeruleus (LC), dorsal raphe,
amygdala, and nucleus accumbens. Findings also demonstrate deactivations in the
hypothalamus and hippocampus. This trial differs from prior trials as the stimulation
duration is highly unconventional and longer than any of the prior behavioral or imaging
trials (7min stimulation of target sites with only one block each). No forebrain findings
were discovered and imaging the deep mid brain and brain stem activation validity are
still debated amongst imaging experts.
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The most recent taVNS/fMRI trials were conducted by Yakunina et al. in 2016. This
study explored brainstem activations (NTS and LC) of four different stimulation sites on
the ear (inner tragus, posterior wall of ear canal, cymba conchae, earlobe control). Not
only did it have the most stimulation sites of any study, it also recruited the highest
number of subjects of any prior taVNS trial (37 healthy individuals)(89). Stimulation was
delivered at 500µs, 25Hz for 6min ON blocks. Both earlobe and posterior ear canal
stimulation sites produced the weakest NTS and LC activation, whereas the tragus and
concha targets produced robust brainstem (vagal mediate) activations. When tested head
to head, the concha was revealed to be the optimal stimulation site to activate the NTS
and LC. This study suggests the concha may be a better target than the tragus.

It is important to note that all fMRI trials have widely varied methodology. They employ
different stimulation parameters, stimulation durations, and whether a control was used or
not. These studies, their differences and findings are summarized in table 4-1. The field
of taVNS still lacks a consensus on many of these stimulation targets are highly debated
within the small field.

Study Introduction and Hypothesis
Prior studies described in Chapters 2 and 3 of this dissertation attempted to determine
whether optimal taVNS parameters could be discovered using parasympathetic decreases
in HR as measures. Although it was determined that larger pulse widths and higher
frequencies of parameters modulate the parasympathetic response greater than lower
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parameters and control, it is still unknown whether taVNS has a direct effect on the
afferent vagal pathway of the central nervous system. It has been suggested via fMRI
studies that stimulation of the ABVN has afferent brain effects that are initiated via the
brainstem (89, 93) although there have been no neck dissection studies looking at the
connection of the ABVN to the main bundle or the brainstem. There is mixed, limited
fMRI data on the afferent effects of taVNS, with studies varying in stimulation duration
and parameter.

One of the optimal parameter candidates from the initial physiological trials described in
Chapter 2 was used to explore the direct brain effects of taVNS using concurrent
taVNS/fMRI. We hypothesize that by using parameters known to have a biologic effect
in our prior trials relevant and significant brain activation changes in afferent vagal
pathway areas as measured by BOLD fMRI.

Methods
Overview
We conducted a 2-visit, single blind, sham-controlled, crossover fMRI trial exploring the
effects of active taVNS stimulation compared to earlobe stimulation (control).
Participants attended 2 scanning visits, separated by at least 1 day apart to avoid any
carryover effect. All scanning was conducted at the MUSC Center for Biomedical
Imaging 30 Bee Street location. This study was approved by the MUSC Institutional
Review Board (IRB) and is registered on ClinicalTrials.org (NCT02835885).
86

Table 4-1. Prior taVNS/fMRI Trials
taVNS/fMRI studies
Year
2007

Author
Kraus et
al.

n
22

2008

Dietrich
et al.

4

2013

Kraus et
al.

2015

Subject
s
Healthy
Controls

Control
Conditio
n
Yes
Earlobe

Site
Outer
ear
Canal

Parameters
20µs
8 Hz
30s stim

Findings
−BOLD ↓ in limbic (amg, hp,
parahp g) and the MTG, STG
−BOLD ↑ in insula, PreCG, thal

Healthy
Controls

Inner
Tragus

250µs
25 Hz
50s stim

No

−BOLD ↑ in L LC, L >> R thal, L
PFC, Bl PcG, L PCG, L insula
−BOLD ↓ in R Nacc, R Cb

16

Healthy
Controls

L outer
canal
(ant vs
post)

20µs
8 Hz
30s stim

Yes
Earlobe

Frangos
et al.

12

Healthy
Controls

L
Conchae

250µs
25 Hz
7 min stim

Yes
Earlobe

2016

Yakunina
et al.

37

Healthy
Controls

4 areas

500 µs
25 Hz

Yes
Earlobe

−Ant: BOLD ↓ in parahp g, PCC, R
thal (pulvinar), LC, STN
−Ant and Post: BOLD ↑ in insula;
otherwise oppose signal
directions
−BOLD ↑ signal in L NTS, Bl STN,
DR, LC, cl PBA, Amg, Nacc, bl
paracentral lobule
−BOLD ↓ in hp, hypoth
-BOLD ↑ in Conchae > Tragus >
Canal in both NTS and LC

2017

Badran et
al. (this
study)

17

Healthy
Controls

Tragus

500 µs
25 Hz

Yes
Earlobe

-control = ↑BOLD Postcentral
-tragus = ↑BOLD Postcentral &
Afferent Vagal
tragus>control= ↑BOLD Afferent
Vagal

Bl- bilateral; L-left; R-right; Stim- Stimulation; AMS- Adjective Mood Scale; Brain areas: MFC-Middle Frontal
Cortex; NTS-Nucleus of Solitary Tract; LC-Locus Coeruleus; thal-thalumus, PFC-prefrontal cortex, PreCGPrecentral gyrus; PostCG-Postcentral Gyrus; PCG-posterior cingulate gyrus; Nacc- Nucleus Accumbens; STNspinal trigeminal nucleus; cl PBA- contralateral Parabrachial area; Cb- Cerebellum
*Inner tragus; inferoposterior wall of canal; cymba conchae
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Participants and Inclusion Criteria
17 healthy individuals (8 female) were enrolled after meeting the following inclusion
criteria: age 18-45, no personal or family history of seizure, mood, or cardiovascular
disorders, no facial or ear pain, no recent ear trauma, no metal implants including
pacemakers, not pregnant, no dependence on alcohol or recent illicit drug use, not on any
pharmacological agents known to increase seizure risk (Bupropion, neuroleptics,
albuterol, theophylline, antidepressants, thyroid medications, or stimulants). Participants
were screened for MRI exclusionary criteria as well (metal in body and claustrophobia).

fMRI Scanning
All MRI scanning was conducted using a Siemens TIM Trio 3.0T system and the
provided Siemens 32-Channel head coil. Individuals were positioned head-first supine on
the bed of the scanner and foam pads were used to stabilize the head and minimize
movement.

Each of the two visits lasted approximately 30-minutes in duration during which 3
functional sessions were acquired (Figure 4-1a). Following a localizer scan, a high
resolution anatomical MPRAGE (TR: 1900ms; TE: 2.26ms; Voxel size: 1mm3; 208
slices, FA: 9 deg) was collected. Following the anatomical image, three separate
functional scans were acquired, in which subjects received (either active or sham)
concurrent taVNS. The order of active and sham stimulation was counterbalanced.
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a

c

b

Figure 4-1 Imaging study design. a) Overview of scanning visits and MRI scans
acquired. b) Block design of the concurrent taVNS/fMRI BOLD scans with time on and
off. c) Ear stimulation targets (identical to prior two physiologic trials).
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Lastly, a field map was acquired to correct for distortions due to magnetic field
inhomogeneity.

The concurrent taVNS/fMRI scans were conducted using an echo-planar imaging (EPI)
sequence (TR: 2800ms; 126 volumes, TA: 5:52s, TE: 35ms; Voxel size: 3.0mm3; 47
slices, FA: 76 deg), with a block design (Figure 4-1b). Each scan run was identical,
consisting of an initial 30s “OFF” period with no stimulation, followed by 3, 60s “ON”
periods in which electrical stimulation was delivered to the ear. The time between “ON”
periods was 60s, followed by a final 22s “OFF” period after the final stimulation block.
Each functional session lasted 6 minutes. The stimulation was synchronized with the start
of each taVNS/fMRI BOLD sequence acquisition (from 0:00 and ran to 5:52 for each
taVNS/fMRI run) and was triggered upon first fMRI volume acquisition in the equipment
room using an automated stimulation system that delivered TTL pulses to the constant
current stimulator at specific frequency and duration. Timing validation was confirmed
with the console timer after each individual stimulation session. Upon completion of each
taVNS/fMRI scan, individuals were asked through intercom how many stimulation
blocks they felt in order to verify signal transmission into the scanner and all three “ON”
blocks were delivered. They were also asked to rate their pain on a NRS from 1 (no pain)
-10 (extreme pain)
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Concurrent taVNS/fMRI System
Stimulation was delivered via custom developed stimulating electrodes pictured in
Figure 4-2a. Computer assisted drawings of the electrode clamps (Figure 4-2b) were
generated in SketchUp (Timble Navigation, USA) and subsequently 3D printed out of
ABS plastic at the MUSC Brain Stimulation Laboratory (Flashforge Creator Pro, China).
The round, unipolar stimulation electrodes were 1cm in diameter made of Ag/AgCl and
affixed to the 3D printed clamps using cyanoacrylate. Copper was used for all wiring.
Ten20 conductive paste was used as a conductor for the electrodes.

Constant current stimulation was delivered using a Digitimer DS7a set to <400V. Lead
wires were attached to the Digitimer output and connected to a radio frequency (RF)
patch panel in the wall between the equipment room and magnet room using a serial
connector on both sides. Figure 4-3 demonstrates the taVNS/fMRI setup visually. Wire
was run from the patch panel in the magnet room towards the foot of the MRI scanner,
where it was then run on top of the participant who was laying supine head first on the
scanning table. ½ inch PVC piping was used to insulate the wires and rested on the
participant’s abdomen and the stimulation electrodes were clamped to the individual’s
tragus or earlobe depending on condition.

taVNS Parameters and Stimulation Targets
The parameters used for this fMRI trial were 500µs 25Hz (monophasic square waves)
based on previous autonomic effects described in Chapters 2 and 3 of this
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Figure 4-2 fMRI compatible electrodes a) picture of final taVNS electrodes that have
been 3d printed and assembled b) CAD drawings of electrodes demonstrating the 3-piece
design and “U” shaped spring clip. Ag/AgCl electrodes were affixed to the inside part of
the electrode clips.
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Figure 4-3 taVNS/fMRI Setup. This figure shows how taVNS is synchronized and
delivered to the scanner. Timing is driven off the control room main console computer.
Triggering of the direct current stimulator occurs in the equipment room which
propagates an electrical stimulation current through a grounded RF filter and into the
magnet room through a 10m cable that attaches to the participant’s ear in the scanner.
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dissertation. Stimulation current was set to 200% of perceptual threshold (PT) and the PT
was determined while the subject had electrodes attached and was lying in the scanner.
Perception of stimulation was relayed to the equipment room via intercom and the current
modified until the participant felt the minimum perceptual level. Active stimulation was
delivered to the left tragus, control stimulation to the left earlobe (Figure 4-1c).

Data Processing and Analysis
All images were converted from DICOM to NifTI using dcm2nii program. All further
processing and analysis was performed in SPM 12 software (UCL) using MATLAB
R2012a (The MathWorks Inc, Natick, MA). First, deformations required for
normalization were derived from whole brain anatomical images using Segment. Skull
stripped anatomical images were created from grey matter, white matter and CSF masks
with Image Calculator to improve functional to anatomical coregistration. Next, the
functional images were processed through Realign and Unwarp to reduce motion related
variance and correct distortions due to magnetic field inhomogeneities. The mean image
from realignment was coregistered to the skull stripped anatomical image using a
normalized mutual information algorithm. The estimated coregistration parameters were
combined with the forward deformations applied to the functional data in a single step to
bring the data into MNI space. Finally, the data was smoothed using an 8mm FWHM
Gaussian smoothing kernel. Estimated movement parameters were examined and no
participants exceeded our movement threshold of one voxel.
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For subject level general linear modeling, the three stimulation “ON” periods (onset
times: 30s, 150s, 270s; duration 60s) were convolved with the canonical hemodynamic
response provided by SPM. Estimated motion parameters were included in the model as
nuisance regressors and the data was high pass filtered with a cutoff of 180 seconds. Each
subject’s contrast estimates for stimulation “ON” condition was combined into a second
level model in which two separate group analysis were conducted (active group only,
control group only) using a one-sample t-test (active: ON>OFF, ON<OFF; control:
ON>OFF, ON<OFF). The duration of the “OFF” time was unmodeled and left as the
implicit baseline. Additionally, an overall paired t-test contrast was also conducted
(active ON>OFF > control ON>OFF; active ON<OFF > control ON<OFF). Lastly, a
brain stem mask was created in order to explore if regional activations in this small area
could be detected in each of the group analyses.

Results
Participants, Stimulation, and Tolerability
17 healthy, right-handed individuals (8 female, 9 male, mean age 25.8 SD 7.59) were
included in this study. All participants completed both visits without any dropouts. Mean
perceptual thresholds (PT) are as follows (mean ± SD mA): tragus 1.57 ± 0.48; earlobe
1.22 ± 0.58. The current at which taVNS was delivered was again a scale multiplier of
the PT (200%). Mean stimulation currents were as follow (mean ± SD mA): tragus- 3.14
± 0.99; earlobe 2.43 ± 1.16. Using a 2-tailed paired t-test, it was determined that there
was no difference in perceptual threshold between the two stimulation sites (table 4-2).
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Mean NRS scores were low, with the mean difference in pain rating between active and
control being 0.6 on a subjective 1-10 scale in 0.5 increments (table 4-2). Although a
paired t-test revealed this difference in pain ratings is significant, in practicality
stimulation should be considered painless in both conditions, as maximum of 2.1 (mean
active pain rating) on a 1-10 rating scale is insignificant pain.

Whole-Brain fMRI Analysis
Earlobe (control condition) Stimulation Only
In the control group analysis exploring the BOLD signal changes during left earlobe
stimulation, statistically significant increases in BOLD signal associated with stimulation
(ON>OFF) were only found in the right inferior postcentral gyrus, operculum, and insula
(n=17, one sample t-test, cluster FWE p<0.05, cluster forming threshold p <0.005, extent
threshold =100 voxels) (Figure 4-4, Table 4-3). There were areas in which a significant
decrease of the BOLD signal below the baseline was found (ON<OFF contrast).
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Table 4-2. Mean PT, current, and pain ratings during stimulation

PT ± SD (mA)

Tragus

Earlobe

Significant?

(Active)
1.57 ± 0.48

(Control)
1.22 ± 0.58

(p value)

N

Stim. Current ±
SD (mA)

3.14 ± 0.99

2.43 ± 1.16

2.1 ± 0.87

1.43 ± 0.68

Mean 500us 25Hz
NRS Pain Rating
± SD
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Y (p<0.01)

Figure 4-4 Earlobe (Control) Stimulation Only a) fMRI BOLD activations resulting
from control stimulation only (compared to rest). (n=17, one sample t-test, cluster FWE
p<0.05, cluster forming threshold p <0.005, extent threshold =100 voxels).
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Tragus (active condition) Stimulation Only
In the active group analysis exploring the BOLD signal changes during left tragus
stimulation condition, statistically significant increases in BOLD signal associated with
stimulation (ON>OFF) were found in similar areas as earlobe stimulation (right
postcentral gyrus, operculum, and insula) as well as other more wide spread areas such as
the left insula, angular gyrus, cerebellum, and bilateral frontal lobes (n=17, one sample ttest, p<0.05 FWE corrected, cluster forming threshold p <0.005, extent threshold =100
voxels) (figure 4-5, table 4-3). No significant deactivations were found (ON<OFF
contrast).

Tragus (active) Greater Than Earlobe (control)
The effect of control stimulation was subtracted from the effect of active stimulation to
analyze the group effect of taVNS compared to control. From this analysis, one can
visualize the effects of active taVNS in two contrasts (ON>OFF, ON<OFF). When
examining areas in which active stimulation was greater than control, significant clusters
were found in the right mid cingulate, caudate, bilateral operculum, bilateral cerebellum,
and bilateral anterior cingulate cortex (ACC) (paired t-test, p<0.05 FWE corrected,
cluster forming threshold p <0.005, extent threshold =100 voxels) (Figure 4-6, Table 43). No areas were found in which active stimulation led to a lower response than control.
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Figure 4-5 Tragus (Active) Stimulation Only a) fMRI BOLD activations resulting from
tragus stimulation only (compared to rest) (n=17, one sample t-test, cluster FWE p<0.05,
cluster forming threshold p <0.005, extent threshold =100 voxels).
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Figure 4-6 Active stimulation > control stimulation a) fMRI BOLD activations
resulting from the contrast active > control stimulation only. (n=17, paired sample t-test,
cluster FWE p<0.05, cluster forming threshold p <0.005, extent threshold =100 voxels).
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Table 4-3. Results from GLM analyses for active and control stimulation.

pFWE-corr

Cluster Statistics
# voxels

Cluster Locations
puncorrected

x

Peak Location (MNI)
y
z

Left Earlobe (Control) Stimulation
0.007

165

Left Tragus (Active) Stimulation Only
0
1491

0.011

359

0.001

Right Central Operculm
Right Postcentral Gyrus
Right Insula

48
63
36

-4
-16
-13

8
23
17

0

Right Insula
Right Central Operculum
Right Postcentral Gyrus

36
48
60
-36
-39
-39
-42
-48
-36
-9
-9
-9
-15

-13
-7
-16
-16
-7
2
41
44
50
23
38
35
-70

17
8
32
11
2
-10
-1
-16
-16
47
47
47
-46

27
15
18
3
36
-18
3
-12
-9
-30
-12
-12

-7
2
-4
-58
-58
-67
35
26
14
14
26
38

35
23
38
-43
-37
-40
11
17
23
35
44
35

0.001
Left Insula

0.007

392

0

Left Angular Gyrus
Left Inferior Frontal Gyrus

0.077

221

0.005

Left Supplementary Motor Area
Left Superior Frontal Gyrus
Right Superior Frontal Gyrus
Left Cerebellum

0.082
217
0.006
Active Stimulation > Control Stimulation
0.005
369
0

0

698

0

0.007

353

0

0.053

221

0.003

Right Caudate
Right Mid Cingulate Gyrus
Bilateral Cerebellum

Bilateral Anterior Cingulate
Left Anterior Cingulate
Left Mid Cingulate
Left Mid Frontal Gyrus
Left Superior Frontal Gyrus
Left Superior Frontal Gyrus
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Brain stem analysis
A post-hoc, brainstem analysis was conducted using an explicit mask comprised of the
pons, midbrain, and medulla (121). Using the same thresholds on this limited region, no
significant findings were discovered in either condition (active only, control only) or in a
direct comparison contrast (active vs control).

Discussion
Using this taVNS/fMRI system, we have demonstrated that active taVNS in healthy
young adults at 500µs 25Hz produces significant BOLD activations throughout cortical,
subcortical, and cerebellar brain regions associated with the afferent vagal pathway. In
contrast, control stimulation of the earlobe exclusively produces a contralateral
somatosensory BOLD signal response in the postcentral gyrus representation of the face.
When control response is subtracted from the active response in the overall contrast of
active>control, significant activations emerge throughout the cingulate gyrus (bilateral
ACC, bilateral mid cingulate), frontal cortex (left middle and frontal gyrus), cerebellum,
and right caudate.

We investigated the direct brain effects of taVNS to either the left tragus (active) or
earlobe (control) using a novel taVNS/fMRI paradigm in 17 healthy individuals. Each
participant attended two scanning sessions, in which both left tragus (active) and left
earlobe (control) stimulation was administered in order to determine the afferent brain
effects of electrical stimulation of the ABVN. Within this trial, we describe two effects:
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1) the somatosensory cortical representation of the ear, and 2) the cortical and subcortical
direct brain effects of stimulating the ABVN.

Penfield described the homuncular representation of the human primary sensory cortex
(122), and notably the ear is omitted from these trials. To date there have only been two
studies exploring ear somatosensory representation (123, 124), the first using
magnetoencephalography (MEG) and the second using fMRI. Both describe the
somatosensory response of the left ear being represented on the contralateral
somatosensory cortex in the face and neck areas. The MEG findings demonstrated that
somatosensory evoked magnetic fields (SEFs) were produced in response to slow (1Hz),
ultra brief (0.05ms pulse width) electrical stimulation of the earlobe. The follow-up MRI
findings by the same group confirm initial MEG findings that slow (2Hz), brief (0.5ms
pulse width) electrical stimulation solely activates contralateral postcentral gyrus.
Although our stimulation current was faster (25 Hz compared to 1 and 2 Hz), the pulse
width was identical and our control stimulation findings replicate these two sequential
trials conducted by Nihashi et al.

The afferent pathway of the ABVN is still poorly understood although it is hypothesized
to activate the main vagal afferent pathway (via the NTS, LC, and upstream cortical
projections as described in detail in Chapter 1) (13, 125-127). To date, excluding this
trial, there have only been five taVNS/fMRI studies exploring the direct brain effect of
electrical stimulation to the ear listed in table 4-1. The findings are widely variant as are
104

the methods. We have understood from prior heart rate trials described in Chapters 2 and
3 that pulse width and frequency affect the stimulation-induced parasympathetic effect of
taVNS. This was also described in a VNS/fMRI trial exploring pulse width effect on
BOLD (49) Unfortunately two of the prior trials explored 250µs pulse width stimulation
(90, 93) and two others administered 20µs stimulation (91, 92). Our trial used a 500µs
25Hz parameter similar to Yakunina et al (89) with similar findings. Like the Yakunina
group, we demonstrate tragus stimulation produced significant increased activation in the
angular gyrus, caudate, cerebellum, cingulate, and frontal cortex. These regions in
general are also found activated throughout the other smaller pulse width trials listed in
Table 4-1 and are afferent targets of the vagus nerve pathway, suggesting ABVN
stimulation enters the vagal bundle and projects to the brain via the brainstem.

A major difference between these trials was the time of stimulation during scanning.
Three studies stimulated for less than 1 minute (90-92), while the most recent two
stimulated for six or seven minutes (89, 93). In our trial, stimulation was delivered for 1
minute blocks. The studies conducting long stimulation periods reported BOLD signal
activations in the brainstem region, while the prior three trials did not. It is difficult to
image small brainstem regions such as the LC and NTS without rapid, thin slice
acquisition of that region. Even in perfect conditions the breathing, moving, and
swallowing artifacts make imaging this region of the brain a challenge. It is plausible that
we did not see any brainstem activations due to our short stimulation period of 1 minute

105

and possible future studies should consider longer stimulation periods and scans
optimized for imaging the brainstem rather than whole brain scans.

Interestingly, the strong bilateral activation of the ACC and left DLPFC may reveal a
potential mechanism for the anti-depressant effect of cervically implanted VNS as well as
taVNS that has been described in the literature (33, 40, 88). It has been demonstrated
that the ACC is involved in cognition and emotional processing (128, 129)and has been
shown to play a key role in the depressions, expressing reduced glutamate release (130132)and reduced glial cell density (133, 134) in pathologic conditions. It also has been
used as a longitudinal predictor of treatment response in depression (135, 136). The left
DLPFC has been demonstrated to be hypoactive in depression (137, 138) and is targeted
with high frequency rTMS (139-142). Presented with significant BOLD activations in
regions of the brain associated with major depression, it is reasonable to consider a
bottom-up approach to treating MDD. Rather than pharmacological agents aimed at
neurotransmitters, or rTMS which treats the cortex, taVNS can potentially target desired
brain regions by entering the brain through cranial nerves and having a cortical effect
driven from the brainstem.

Limitations
It is important to recognize some limitations in our trial. Firstly, we chose a 1 minute
stimulation period was chosen to be consistent with our prior physiological trials. The
safety profile of longer periods of stimulation was unknown and we did not want to risk
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adverse events in the MRI scanner. Secondly, we acknowledge that there may residual
cortical brain effects persisting in the 60s inter-stimulation rest blocks. This type of
design was used to increase the power of our effect by increasing number of stimulation
blocks while minimizing scanner drift of long stimulation trials. Lastly, the control region
was chosen as the earlobe in line with prior taVNS trials, although it may not be the most
reliable as some individuals may have ABVN projections spanning to the lobule of the
ear.

Conclusion
These findings demonstrate taVNS delivered at 500µs 25Hz to the left tragus produces
significant cortical effects in the vagal afferent pathway compared to earlobe stimulation.
These findings are similar to prior taVNS trials. Furthermore, bilateral ACC and left
prefrontal BOLD signal increases shed light on the ability to conduct bottom-up brain
stimulation modalities in which stimulating cranial nerves can potentially be used as
therapeutics. Future taVNS/fMRI trials should be conducted to explore the effect of
parameter and stimulation duration on the BOLD signal response.
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CHAPTER 5
CONCLUSIONS and FUTURE DIRECTIONS

Summary of Findings
This body of work aimed to address five goals. They are listed below along with their
summarized overall findings in their respective subsections.
1. Develop a system that stimulates the ABVN at MUSC
2. Determine if taVNS is safe
3. Optimize stimulation parameters using heart rate as a biomarker
4. Develop and optimize a taVNS/fMRI method
5. Measure the direct brain effects of taVNS using BOLD fMRI

Develop a system that stimulates the ABVN at MUSC
This body of work began in 2014, and at that time there was one commercially available
ABVN stimulation unit on the market sold under the name NEMOS© (Cerbomed
GMBH, Germany). It is not sold in the United States, and there were several issues
associated with using a commercially available device. Firstly, stimulation parameters
(pulse width, frequency, duration) are not modifiable making it difficult to use them in
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laboratory-controlled trials. Secondly, the stimulation electrodes target the cymba
conchae of the ear, which is a different primary site of active stimulation than had been
chosen for these trials (tragus stimulation/ear canal). As of 2017 this commercially
available company has unfortunately declared bankruptcy and no longer sells these
devices. For these reasons, it became important to develop a standalone, independent
system at MUSC that has completely modifiable parameters and ability to stimulate
various ear targets.

A stimulation electrode was built by Bashar and Alan Badran, made of 1cm diameter
round cup electrodes (cupped in order to hold conductive gel) that were affixed to each
other in a custom clip arrangement, forming what are essentially direct electrical current
clamps that can stimulate either the tragus (active) or earlobe (control). These are
pictured in the Methods section of Chapter 2.

In order to avoid filing an Investigational Device Exemption (IDE) with the FDA as
required by the MUSC IRB, the constant current stimulator used was required to be
FDA-cleared. The custom electrodes were modified to be compatible with the Digitimer
DS7a stimulator, which was used for all three stimulation trials. This stimulator allowed
for easy and reliable parametric modifications, most importantly changing pulse width,
frequency, current, and stimulation duration. The custom electrodes paired with the
stimulator allowed for a variety of experimental taVNS studies to be easily conducted.
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Determine if taVNS is safe
Given the parasympathetic efferent projections of the vagus nerve described in Chapter 1,
the primary safety concern was the potential of adverse cardiac events. Cervically
implanted VNS has a long history of animal and human safety and feasibility trials(36,
42, 99, 100). taVNS is a relative newcomer, having been formally proposed in 2000 and
lacking the large number of prospective human trials. There had been several prior
reports that were published while the safety trials were conducted suggesting its safe use
(84, 88, 143-145), although parameters were highly inconsistent and variable.

The first subjects of our initial HR trial were conducted in the electroconvulsive therapy
suite at MUSC. Dr. Mark George was the first subject to receive stimulation from our
custom taVNS system. Before the experimental visit started, Dr. George asked Bashar
“Do you know how to call 9-1-1?” Retrospectively, that comment sounds rather
egregious, but it accurately conveys the perceived safety risk and concern of the research
team working with this new modality.

Our systematic testing of the effects of nine different taVNS parameters on immediate
decrease in heart rate established that 1-minute stimulation sessions of tragus stimulation
elicits a safe, relatively minor decrease in heart rate during stimulation. No adverse
events were reported in any of the three trials conducted. Redness was perceived at the
stimulation site that resolved after several minutes. taVNS was determined to be safe in
our stimulation paradigms.
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Optimize stimulation parameters using heart rate as a biomarker
We conducted two physiological trials exploring the effects of taVNS on HR described in
Chapters 2 and 3 of this dissertation. The first trial in 15 healthy individuals revealed no
overall effect of active taVNS (vs control) in heart rate during the stimulation period.
Upon multivariate analysis of each of the nine individual parameters, significant effects
on HR were discovered in several parameters, suggesting the parasympathetic activation
via taVNS is parameter specific. The optimal parameters at modulating HR in this trial
were 500µs 10Hz and 25Hz.

Following this initial study, we conducted a follow-up confirmatory study was conducted
in 20 healthy individuals exploring the effects on HR of the two optimal parameters
(500µs 10Hz, 500µs 25Hz) against each other and against control stimulation. In this
trial, when both parameters were combined, active taVNS produced significant decreases
in HR during stimulation period compared to control stimulation. Upon individual
parameter analysis, both parameters produced decreases in HR during the stimulation
period, although the optimal parameter determined to activate parasympathetic decrease
in HR compared to control was 500µs 10Hz. These sequential trials suggest parametricspecific effects of taVNS on the parasympathetic nervous system possibly modulated by
the ABVN and vagal pathway.
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Develop and optimize taVNS/fMRI method
We developed a non-ferromagnetic MRI-compatible system that can safely and reliably
stimulate the ABVN through the tragus and earlobe in order to conduct taVNS in the
magnetic field of the fMRI scanner. As described in Chapter 4 were the three roadblocks
(heating of electrodes, induced currents, MRI artifact) were surmounted using a variety of
electronic and manufacturing achievements. Electrodes were fabricated out of 3D printed
plastic and Ag/AgCl materials; 5kΩ resistors were placed in the copper stimulation wires
(insulated with PVC); and a grounded RF filter attached to a patch panel in the wall
adjacent to the scanner room was used to solve all these potential pain points.

After fabrication of all components, three separate quality control scans were conducted
on MRI phantoms in order to confirm electrical stimulation in the MRI scanner did not
disrupt the image acquisition and that heating was minimal. Subsequently two pilot scans
were completed on healthy individuals to confirm scanning was feasible and safe. This
development process created one of less than five MRI-compatible taVNS systems in the
United States as of 2017.

Measure the direct brain effects of taVNS using BOLD fMRI
We conducted a two-visit trial in 17 healthy individuals in which participants received
either active (tragus) or control (earlobe) taVNS stimulation (via our custom
taVNS/fMRI system), while imaging the direct brain effects using fMRI. The control
stimulation only group analysis revealed significant BOLD activation in exclusively the
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primary somatosensory cortex while the active stimulation only group produced
significant global cortical and subcortical BOLD activations. Of note, active taVNS
activated the bilateral insula, bilateral frontal cortex, and similar somatosensory
activation as control.

The main contrast explored the overall BOLD effects of taVNS significantly greater than
control (active>control, paired t-test), which revealed significant activations in the
bilateral anterior cingulate, bilateral cerebellum, left frontal cortex, and right caudate.
These findings suggest taVNS stimulates the afferent vagal pathway, supporting the
hypothesis that the ABVN that innervates the ear most likely joins the main vagal bundle
and enters the brain to affect similar neuroanatomical structures. These data are in line
with the few taVNS/fMRI studies in the literature. Of notable difference, this study did
not discover any brainstem or midbrain activations, as suggested by two of the prior
trials. Further discussion regarding this topic can be found in the Discussion section of
Chapter 4.

Limitations
Heart Rate Trials
There are three limitations to consider and improve upon from these heart rate trials.
Firstly, one cannot be certain that stimulating the tragus or any part of the ear is directly
stimulating the ABVN. There is one prior study in which dissections of the ear reveal the
underlying nerves (81). It is revealed that only 45% of the dissections in their sample
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contained ABVN innervation in the tragus and ear canal. This plausibly can introduce the
high level of variance between individual effects of taVNS, especially at low stimulation
parameters. It is nearly impossible to determine the nerve innervation in individual
participants before conducting a trial, so this limitation may persist until noninvasive
subcutaneous nerve mapping technology becomes available.

Secondly, there is a decrease in heart rate that is sustained in the control group. It is still
unknown what causes this bradycardia. One hypothesis is that this earlobe-induced
bradycardia could be due to “electrical bleed” from the earlobe to closely innervating
ABVN projections. The distance between the earlobe and tragus is less than 3cm on
average, and of all possible controls, earlobe stimulation is arguably the most stringent.
Studies like this require these active control sites to definitively conclude the findings.

Lastly, perhaps heart rate is not the most effective surrogate marker of vagal activity in
taVNS trials, especially given the bidirectional communication of the vagal nerve. It is
difficult to determine whether the effects on HR are due to direct efferent projections to
the heart (ear->heart) or whether these effects are relayed up (afferent pathway) to the
brainstem and loop back down to target efferent targets.

fMRI Trial
A major limitation in the fMRI trial is that the stimulation time (60s) may not have been
long enough to capture the BOLD signal response to stimulation in the brainstem. This
114

trial was only the sixth taVNS/fMRI exploring the afferent effects of ABVN stimulation
(See Chapter 4, Table 1), and only two of the prior studies (89, 93) demonstrated
brainstem effects that suggest ABVN stimulation enters the brain via the NTS in an
identical manner as the cervical vagus nerve. One trial stimulated an “ON” period of 6
minutes, and another trial stimulated an “ON” period for 7 minutes. The remaining trials
with short stimulation periods reveal no brain stem activity. It is difficult to say that it is
strictly due to stimulation time, as imaging that region of the brain is extremely difficult
to image.

Future Directions
Further Optimization of Parameters
These trials, although highly promising, are not conclusive as to whether a higher pulse
width of 500µs or higher frequencies of 10-25Hz are the optimal stimulation parameters
for taVNS. Although these results demonstrate biologic effects on heart rate and central
effects of the vagus afferent projections measured by fMRI, further parametric
optimization needs to be conducted.

These physiological trials were conducted in a laboratory setting with individuals laying
supine and a resting HR. This was considered a conservative position and paradigm for
exploring effects of a parasympathetic modulator. Future parametric explorations should
be conducted in high stress situations in which the sympathetic nervous system is active
and attempt to modulate it by activating the reciprocal parasympathetic nervous system.
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This may yield larger effect sizes and possibly decrease the amount of response earlobe
stimulation produces. Potential autonomic blockade with pharmacological agents could
also be used to knock out the active taVNS potential effect.

Conducting parametric explorations of taVNS will be integral in moving this technology
forward. Similar to a pulse-width study conducted at MUSC with cervical VNS/fMRI
(146, 147), various pulse widths and frequencies can be conducted in the MRI scanner
and capture the neurophysiological signature of the stimulation. These fMRI studies are
time and cost intensive, so it would be prudent to conduct trials exploring taVNS on
surrogate markers of vagus activation or EEG before going into the fMRI scanner, similar
to how these sequential HR and fMRI trials were conducted.

Aside from pulse width and frequency, duty cycle must be explored. Given the BOLD
signal changes observed in longer stimulation periods (>6 minutes), perhaps taVNS is not
as powerful as cervically implanted VNS. All taVNS trials are following the parameter
space of cervically implanted VNS described in the early 1990’s (23, 24, 148), although
the mechanism and fibers could be completely different when delivered through the ear.
There are only disperse nerve projections in the ear rather than the large bundle of the
vagus nerve and it is plausible that rather than mimicking the short “ON” period of
therapeutic VNS, longer “ON” periods must be explored in future therapeutic trials to
potentially deliver identical signals to the brainstem.
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Perhaps rather than pulse width, frequency, or stimulation time being the issues, the
strength of electrical stimulation may have been under-dosed, possibly limiting the
robustness of the effects Our studies reveal at 200% PT, taVNS is painless, rating on
average a 2.1 on a 1-10 scale. Aside from safety concerns which were appeased during
preliminary trials, future studies should potentially explore increasing dosage to 3-400%
PT in order to determine whether stimulation intensity matters, or maintaining a lower PT
and administering bilateral taVNS to double the signal entering the brain. The field of
taVNS is still very new and these parameters must be worked out in order to have an
effective noninvasive modality.

taVNS Induced Plasticity & Therapeutic Potential
A budding area of VNS research is the area known as targeted plasticity (66),
championed by a team of researchers at the University of Texas, Dallas. This team has
demonstrated that stimulating the cervical vagus nerve in conjunction with various
therapies produces significant cortical reorganization properties as measured by single
channel electrode recordings in rodents (70). Most notably, this pairing of VNS with
specific audio tones has been shown to treat and reverse tinnitus (65, 68) and paired with
rehabilitation paradigms to restore motor behavior in stroke (69, 149). These paradigms
have been successfully translated from animal models to human clinical trials (71-73) and
It is conceivable that these targeted plasticity findings can feasibly and easily be
translatable with taVNS without the cost or risk of surgical implantation.
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Pairing taVNS with specific therapy has yet to emerge as an area of study. There are two
open label, small sample trials which attempted taVNS paired with tones to treat tinnitus
(87, 150) with minimal effects. These findings could be more promising if the proper
stimulation parameter optimization is conducted beforehand. Aside from paring taVNS
with tones, there have been no other paired taVNS trials and this area needs to be
explored as a potential treatment modality.

taVNS can be used in a similar manner as conventional VNS where pulses are delivered
constantly for a long period of time (months to years). It is still unknown what the
optimal dosing paradigm would be, as cervical VNS cycles between on and off periods
constantly for many years until the battery needs to be replaced. Suggested daily use
sessions on the scale of hours would likely be a starting point of therapeutic delivery.
Many of the animal and human studies exploring the use of implantable VNS for central
and peripheral disorders described in Chapter 1, such as epilepsy, depression, obesity,
stroke, and heart disease could be explored with taVNS and easily translated to humans
(98, 151-155). There have been some early trials exploring the use of various parameters
of taVNS for the treatment of depression (88, 156, 157), autism (158) tinnitus (85) and
pain (159-161) all revealing small effect sizes and mixed results.

The main problem encountered with taVNS as a take home therapy is the lack of
practicality as a long term therapeutic modality. The majority of patients that will respond
to cervically implanted VNS therapy for epilepsy or depression do so 12 months post118

implantation (162). This delayed response would require daily use of a taVNS device for
multiple sessions per day, over a period of at least one year while maintaining patient
compliance. More realistically, taVNS will most likely be used as an intermediary device
that will predict response, guiding which individuals would make good candidates for
surgical implantation rather than used as a long term therapeutic modality.

This body of work aims to take the first step in optimizing taVNS. For taVNS to become
a possible future noninvasive therapeutic device in the future, further development is
needed before rushing to clinical trials. Using physiological measures along with
functional neuroimaging trials such as fMRI BOLD to determine optimal stimulation
parameters will lead to more effective, noninvasive treatments for a variety of
neuropsychiatric and peripheral disorders.
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